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Statistical Methods For Multi-Omics Inference From Single Cell Transcriptome 
Abstract 
This thesis comprises three sections of research in statistical genomics and computational biology. 
Chapter 1 and Chapter 2 describe two statistical methods for multi-omics inference from single cell 
transcriptome, representing the theme of this thesis. Chapter 3 describes a side-project on copy 
number variation detection in large biobank data base. 
Part 1: Although scRNA-seq is now ubiquitously adopted in studies of intratumor heterogeneity, detection 
of somatic mutations and inference of clonal membership from scRNA-seq is currently unreliable. We 
propose DENDRO, an analysis method for scRNA-seq data that detects genetically distinct subclones, 
assigns each single cell to a subclone, and reconstructs the phylogenetic tree describing the tumor’s 
evolutionary history. DENDRO utilizes information from single nucleotide mutations in transcribed regions 
and accounts for technical noise and expression stochasticity at the single cell level. The accuracy of 
DENDRO was benchmarked on spike-in datasets and on scRNA-seq data with known subpopulation 
structure. We applied DENDRO to delineate subclonal expansion in a mouse melanoma model in 
response to immunotherapy, highlighting the role of neoantigens in treatment response. We also applied 
DENDRO to primary and lymph-node metastasis samples in breast cancer, where the new approach 
allowed us to better understand the relationship between genetic and transcriptomic intratumor variation. 
Part 2: Recent technological advances allow the simultaneous profiling, across many cells in parallel, of 
multiple omics features in the same cell. In particular, high throughput quantification of the transcriptome 
and a selected panel of cell surface proteins in the same cell is now feasible through the REAP-seq and 
CITE-seq protocols. Yet, due to technological barriers and cost considerations, most single cell studies, 
including Human Cell Atlas (HCA) project, quantify the transcriptome only and do not have cell-matched 
measurements of relevant surface proteins that can serve as integral markers of cellular function and 
targets for therapeutic intervention. Here we propose cTP-net (single cell Transcriptome to Protein 
prediction with deep neural network), a transfer learning approach based on deep neural networks, that 
imputes surface protein abundances for scRNA-seq data. Through comprehensive benchmark 
evaluations and applications to HCA and AML data sets, we show that cTP-net outperform existing 
methods and can transfer information from training data to accurately impute 24 immunophenotype 
markers, which achieve a more detailed characterization of cellular state and cellular phenotypes than 
transcriptome measurements alone. cTP-net relies, for model training, on accumulating public data of 
cells with paired transcriptome and surface protein measurements. 
Part 3: Copy number variations (CNVs) are gains and losses of DNA segments that are highly associated 
with multiple diseases. The Penn Medicine BioBank stores SNP-array and NGS data for more than 10000 
individuals across ethnicity and conditions, providing a rich resource for CNV discovery and analysis. This 
type of experiment design fits perfectly for CNV detection tool - Integrated Copy Number Variation caller 
(iCNV), which I developed as my master thesis. The distinguishing feature of iCNV includes adaptation of 
platform specific normalization, utilization of allele specific reads from sequencing and integration of 
matched NGS and SNP-array data by a Hidden Markov Model (HMM). We applied iCNV on Penn Medicine 
BioBank data set, calling CNV over more than 10000 individuals (~2000 AFR, ~8000 EUR) with different 
phenotypes. iCNV detected on average 34.1 deletions and 11.3 duplications per EUR sample, and 38 
deletions and 10.6 duplications per AFR sample. iCNV calling results show great improvement in 
detection sensitivity and specificity comparing to single platform detection method. Penn Medicine 
BioBank CNV sets by iCNV provide a rich database for researchers to study the relationship between 
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STATISTICAL METHODS FOR MULTI-OMICS INFERENCE FROM SINGLE CELL 
TRANSCRIPTOME 
Zilu Zhou 
Nancy R. Zhang 
This thesis comprises three sections of research in statistical genomics and computational biology. 
Chapter 1 and Chapter 2 describe two statistical methods for multi-omics inference from single cell 
transcriptome, representing the theme of this thesis. Chapter 3 describes a side-project on copy 
number variation detection in large biobank data base. 
Part 1: Although scRNA-seq is now ubiquitously adopted in studies of intratumor heterogeneity, 
detection of somatic mutations and inference of clonal membership from scRNA-seq is currently 
unreliable. We propose DENDRO, an analysis method for scRNA-seq data that detects genetically 
distinct subclones, assigns each single cell to a subclone, and reconstructs the phylogenetic tree 
describing the tumor’s evolutionary history. DENDRO utilizes information from single nucleotide 
mutations in transcribed regions and accounts for technical noise and expression stochasticity at 
the single cell level. The accuracy of DENDRO was benchmarked on spike-in datasets and on 
scRNA-seq data with known subpopulation structure. We applied DENDRO to delineate subclonal 
expansion in a mouse melanoma model in response to immunotherapy, highlighting the role of 
neoantigens in treatment response. We also applied DENDRO to primary and lymph-node 
metastasis samples in breast cancer, where the new approach allowed us to better understand the 
relationship between genetic and transcriptomic intratumor variation.   
Part 2: Recent technological advances allow the simultaneous profiling, across many cells in 
parallel, of multiple omics features in the same cell. In particular, high throughput quantification of 
the transcriptome and a selected panel of cell surface proteins in the same cell is now feasible 
through the REAP-seq and CITE-seq protocols. Yet, due to technological barriers and cost 
considerations, most single cell studies, including Human Cell Atlas (HCA) project, quantify the 
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transcriptome only and do not have cell-matched measurements of relevant surface proteins that 
can serve as integral markers of cellular function and targets for therapeutic intervention. Here we 
propose cTP-net (single cell Transcriptome to Protein prediction with deep neural network), a 
transfer learning approach based on deep neural networks, that imputes surface protein 
abundances for scRNA-seq data. Through comprehensive benchmark evaluations and 
applications to HCA and AML data sets, we show that cTP-net outperform existing methods and 
can transfer information from training data to accurately impute 24 immunophenotype markers, 
which achieve a more detailed characterization of cellular state and cellular phenotypes than 
transcriptome measurements alone. cTP-net relies, for model training, on accumulating public data 
of cells with paired transcriptome and surface protein measurements. 
Part 3: Copy number variations (CNVs) are gains and losses of DNA segments that are highly 
associated with multiple diseases. The Penn Medicine BioBank stores SNP-array and NGS data 
for more than 10000 individuals across ethnicity and conditions, providing a rich resource for  
CNV discovery and analysis. This type of experiment design fits perfectly for CNV detection tool - 
Integrated Copy Number Variation caller (iCNV), which I developed as my master thesis. The 
distinguishing feature of iCNV includes adaptation of platform specific normalization, utilization of 
allele specific reads from sequencing and integration of matched NGS and SNP-array data by a 
Hidden Markov Model (HMM). We applied iCNV on Penn Medicine BioBank data set, calling CNV 
over more than 10000 individuals (~2000 AFR, ~8000 EUR) with different phenotypes. iCNV 
detected on average 34.1 deletions and 11.3 duplications per EUR sample, and 38 deletions and 
10.6 duplications per AFR sample. iCNV calling results show great improvement in detection 
sensitivity and specificity comparing to single platform detection method. Penn Medicine BioBank 
CNV sets by iCNV provide a rich database for researchers to study the relationship between 
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CHAPTER 1  DENDRO: GENETIC HETEROGENEITY PROFILING AND SUBCLONE 
DETECTION BY SINGLE-CELL RNA SEQUENCING 
 Introduction 
DNA alterations, especially single nucleotide alteration (SNA) and epigenetic modulation both 
contribute to intratumor heterogeneity [1], which mediates tumor initiation, progression, 
metastasis and relapse [2, 3]. Intratumor genetic and transcriptomic variation underlie patients’ 
response to treatment, as natural selection can lead to the emergence of subclones that are drug 
resistant [4]. Thus, identifying subclonal DNA alterations and assessing their impact on intratumor 
transcriptional dynamics can elucidate the mechanisms of tumor evolution and, further, uncover 
potential targets for therapy. To characterize intratumor genetic heterogeneity, most prior studies 
have used bulk tumor DNA sequencing [5-12], but these approaches have limited resolution and 
power [13]. 
Breakthroughs in single-cell genomics promise to reshape cancer research by allowing 
comprehensive cell type classification and rare subclone identification. For example, in breast 
cancer, single-cell DNA sequencing (scDNA-seq) was used to distinguish normal cells from 
malignant cells, the latter of which were further classified into subclones [14-16].  For the profiling 
of intra-tumor transcriptional heterogeneity, single cell RNA-sequencing (scRNA-seq), such as 
Smart-seq2 [17], Drop-seq [18], and 10X Genomics ChromiumTM,  is now ubiquitously adopted in 
ongoing and planned cancer studies. ScRNA-seq studies have already led to novel insights into 
cancer progression and metastasis, as well as into tumor prognosis and treatment response, 
especially response variability in immune checkpoint blockade (ICB) [19-26].  Characterization of 
intratumor genetic heterogeneity and identification of subclones using scRNA-seq is challenging, 
as SNAs derived from scRNA-seq reads are extremely noisy and most studies have relied on the 
detection of chromosome-level copy number aberrations through smoothed gene expression 
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profiles.  Yet, as intratumor transcriptomic variation is partially driven by intratumor genetic 
variation, the classification of cells into subclones and the characterization of each subclone’s 
genetic alterations should ideally be an integral step in any scRNA-seq analysis.  
The appeal of subclone identification in scRNA-seq data is compounded by the shortage 
of technology for sequencing the DNA and RNA molecules in the same cell with acceptable 
accuracy, throughput, and cost [27-30]. Although one can apply both scDNA-seq and scRNA-seq 
to a given cell population, the mutation analysis and RNA quantification cannot be conducted in 
the same set of cells.  Although there are now technologies for deep targeted sequencing of 
select transcripts matched with same-cell whole transcriptome sequencing [31, 32], these 
methods are still, in effect, profiling DNA-level variation by sequencing expressed transcripts, and 
are thus subject to the technical issues, especially dropout due to transcriptional stochasticity.  
Subclone detection using scRNA-seq is difficult mainly because only a small portion of 
the SNAs of each cell is expected to be seen in the read output of scRNA-seq. This is because to 
be sequenced, an SNA needs to fall in a transcribed region of the genome, at a location within 
the transcript that will eventually be read by the chosen sequencing protocol.  Even for SNAs that 
satisfy these requirements, the mutated allele are often missing in the read output due to dropout, 
especially in the heterozygous case. This is due, in part, to the bursty nature of gene transcription 
in single cells [33-35], where in any given cell, a substantial fraction of the genes are only 
expressed from one of the alleles. Thus, an SNA residing in a gene that is expressed at the bulk 
tissue level may not be observed in a particular cell, simply because the mutated allele, by 
chance, is not expressed in the given cell. We refer to alleles that are not captured due to 
expression stochasticity as biological dropouts. Even for a mutated allele that is expressed, it has 
to be successfully converted to cDNA and then sequenced to be represented in the final read 
output; we refer to alleles lost due to technical reasons as technical dropouts. In addition to 
dropout events, post-transcriptional modification, such as RNA editing, and sequencing errors 
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impede both the sensitivity and the specificity of SNA discovery. As a result, methods developed 
for single cell SNA detection using scDNA-seq, such as Monovar [36], as well as methods 
designed for SNA detection in bulk DNA or RNA sequencing data do not yield accurate results in 
the scRNA-seq setting [37-42].  
Here we present a new statistical and computational framework – DNA based 
EvolutionNary tree preDiction by scRNA-seq technOlogy (DENDRO) - that reconstructs the 
phylogenetic tree for cells sequenced by scRNA-seq based on genetic divergence calculated 
from DNA-level mutations. DENDRO assigns each cell to a leaf in the tree representing a 
subclone, and, for each subclone, infers its mutation profile. DENDRO can detect genetically 
divergent subclones by addressing challenges unique to scRNA-seq, including transcriptional 
variation and technical noise. A DENDRO clustering of scRNA-seq data allows joint genetic and 
transcriptomic analysis on the same set of cells.  
We evaluate DENDRO against existing approaches, through simulation data sets and a 
metastasized renal cell carcinoma dataset with known subpopulation labels, and show that 
DENDRO improved the accuracy of subclone detection.  We then demonstrate the DENDRO to 
biological discovery through two applications. The first application profiles the treatment response 
in a melanoma model to immune checkpoint blockade therapy.  DENDRO identified a subclone 
that contracted consistently in response to ICB therapy, and revealed that the contraction was 
driven by the high mutation burden and increased availability of predicted neoantigens.  
Transcriptional divergence between the subclones in this model was very weak, and thus the 
neoantigen-driven sub-clonal dynamics would not have been detected without extracting DNA-
level information. In the second application to a breast tumor dataset, DENDRO detected 
subclones and allowed for the joint characterization of transcriptomic and genetic divergence 
between cells in lymph-node metastasis and cells in primary resections.  
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The DENDRO package, implemented in R, is available at 
https://github.com/zhouzilu/DENDRO, where we also provide a power calculation toolkit, 
DENDROplan, to aid in the design of scRNA-seq experiments for subclonal mutation analysis 
using DENDRO.  
 Results 
1.2.1 Method overview 
1.2.1.1 Overview of DENDRO model and pipeline 
Fig. 1.1a shows an overview of DENDRO’s analysis pipeline. Per cell counts of total read 
coverage (𝑁 matrix) and mutation allele read coverage (𝑋 matrix) at SNA locations are extracted 
after read alignment and SNA detection (details in Methods, Fig. 1.2). Based on these matrices, 
DENDRO then computes a cell-to-cell genetic divergence matrix, where entry (𝑐, 𝑐’) of the matrix 
is a measure of the genetic divergence between cells 𝑐 and 𝑐’. Details of this genetic divergence 
evaluation will be given in the next section. DENDRO then clusters the cells into genetically 
distinct subclones based on this pairwise divergence matrix, and selects the number of subclones 
based on inspection of the intra-cluster divergence curve. Reads from the same subclone are 
then pooled together, and the SNA profile for each subclone is re-estimated based on the pooled 
reads, which improves upon the previous SNA profiles computed at the single cell level. Finally, 
DENDRO generates a parsimony tree using the subclone-level mutation profiles to more 
accurately reflect the evolutionary relationship between the subclones.   
1.2.1.2 Genetic divergence evaluation 
Due to the high rates of biological and technical dropout, SNA detection within each individual cell 
lacks sensitivity. We also expect low specificity due to the high base error rate in scRNA-seq 
protocols. Thus, simple distance measures such as the Hamming or Euclidean distances 
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evaluated on the raw SNA genotype matrix or the raw allele frequency matrix do not accurately 
reflect the genetic divergence between cells.  
To more accurately estimate the cell-to-cell genetic divergence, we have developed a 
statistical model that accounts for technical dropout, sequencing error and expression 
stochasticity. Consider two cells, 𝑐 and 𝑐’, and let 𝐼𝑐 and 𝐼𝑐′ index the clonal group to which the 
cells belong. That is, 𝐼𝑐 =  𝐼𝑐′ if cells 𝑐 and 𝑐’ come from the same subclone and thus share the 
same SNA profile. Let 𝑋𝑐 = (𝑋𝑐1, … , 𝑋𝑐𝑚) be the mutation allele read counts for this cell at the 𝑚 
SNA sites profiled, and 𝑁𝑐 = (𝑁𝑐1, … , 𝑁𝑐𝑚) be the total read counts at these sites. We define the 
genetic divergence between the two cells as 
𝑑𝑐𝑐′ = −log
𝑃(𝑋𝑐 , 𝑋𝑐′|𝑁𝑐 , 𝑁𝑐′ , 𝐼𝑐 = 𝐼𝑐′)









𝑃(𝑋𝑐𝑔 , 𝑋𝑐′𝑔|𝑁𝑐𝑔 , 𝑁𝑐′𝑔 , 𝐼𝑐 = 𝐼𝑐′)
𝑃(𝑋𝑐𝑔 , 𝑋𝑐′𝑔|𝑁𝑐𝑔 , 𝑁𝑐′𝑔)
. 
In other words, 𝑑𝑐𝑐′ is the negative log likelihood of the mutation allele counts of cells 𝑐 and 𝑐′, 
given the total read counts and the event that the two cells belong to the same subclone. If 𝑐 and 
𝑐′ have mutations in mismatched positions, this likelihood for 𝑋𝑐, 𝑋𝑐′ conditioned on 𝐼𝑐 = 𝐼𝑐′  would 
be small, giving a large value for 𝑑𝑐𝑐′. By the assumption of independence between sites, 𝑑𝑐𝑐′  is 






 is the contribution of mutation site 𝑔 to the divergence measure. In 
characterizing the conditional distribution for 𝑋𝑐𝑔 and 𝑋𝑐′𝑔, we use a Beta-Binomial distribution to 
model expression stochasticity and a Binomial model to capture sequencing errors and rare RNA-
editing events.  Referring to Fig. 1.1b, mutations residing in bursty genes, such as gene 𝑔, would 
tend to have U-shaped allele frequency distributions and are more likely to be “dropped” due to 
low or zero expression.  In contrary, mutations residing in constitutive (non-bursty) genes, such 
as gene 𝑔′  in Fig. 1.1b, would have bell-shaped allele frequency distributions and can be 
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genotyped more reliably.  Thus, even if the read counts    for the mutation loci residing in genes  
𝑔 and 𝑔′ are identical across two cells (𝑐1 and 𝑐2 in Fig. 1.1c), the locus in 𝑔′  would contribute a 
higher value, compared to the locus in 𝑔, to the divergence between cells 𝑐1 and 𝑐2.   Please see 
Methods for details. 
1.2.2 Accuracy assessment 
1.2.2.1 Accuracy assessment by simulation experiment 
First, we designed a simulation procedure to assess the accuracy of DENDRO versus existing 
approaches and to make realistic power projections for subclone detection (Fig. 1.3a).  Since 
DENDRO is currently the only method for SNA-based subclone detection using scRNA-seq data 
alone, we benchmarked against more straightforward approaches such as hierarchical clustering 
based on mutation allele frequencies and genotypes respectively.  The simulation procedure 
starts with an assumed evolutionary tree, where the leaves are subclones and mutations can be 
placed on the branches. In the absence of prior information, a simple tree structure is used, such 
as the one shown in Fig. 1.3a. Parameters of simulation are (1) total number of mutations, (2) 
total number of cells, (3) the proportion of cells in each clade, (4) the proportion of mutations 
along each branch, and (5) mean read coverage across loci. Some of these parameters can be 
determined using bulk DNA-seq and/or bulk RNA-seq data if available (Methods). Parameters (1-
4) determine the mutation profile matrix (Fig. 1.3a). To get the matrix of alternative allele (𝑋𝑐𝑔) 
and total read counts (𝑁𝑐𝑔) for each mutation loci in each cell, we overlay a reference scRNA-seq 
data with allele-specific read counts onto a designed mutation matrix, which is generated from the 
simulated tree (See Methods for details). This allows the simulated datasets to retain the 
expression stochasticity and sequencing error of real scRNA-seq data. DENDRO is then applied 
to the read count matrices to obtain the subclone clusters, which is then compared with the 
known labels. Accuracy is evaluated by three metrics: adjusted Rand index, capture rate and 
purity (See DENDROplan evaluation metrics in Methods). Such simulation procedure can also 
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facilitate experiment design, as it predicts the expected clustering accuracy by DENDRO given 
sequencing parameters and available bulk data for the tumor (See DENDROplan in Methods). 
Using the above framework, we conducted a systematic evaluation of DENDRO’s 
subclone detection accuracy on an example scRNA-seq dataset with allelic information [43]. The 
results, compiled in Fig. 1.3b shows that DENDRO has better performance than simply clustering 
on mutation allele frequencies or the directly estimated mutation profiles from scRNA-seq data. 
Due to high burstness of the scRNA-seq dataset and limited sequencing depth, we found that Z-
matrix, on average, underperformed in all scenario, indicating the necessity of the DENDRO 
framework. We also quantified how accuracy depends on the mutation burden, mutation read 
depth, mutation distribution, subclone cell proportion, and cell populations (Fig. 1.4 and See 
Methods). Even when there are only 100 mutations with relatively low average coverage (read 
depth equals to 1), DENDRO can still extract meaningful clustering results (average ARI ≈ 0.8). 
More importantly, variation in total expression of genes does not influence DENDRO’s divergence 
measure. DENDRO shows consistent results in simulation analysis between populations of single 
cell type and multiple cell types (Fig. 1.4). This is due to DENDRO’s reliance only on the 
distribution of the mutation allele frequency conditioned on the total read coverage, as illustrated 
by the simulation study (Fig. 1.5). The divergence evaluation reflects solely genetic distance not 
transcriptomic difference, allowing for easy interpretation.  
1.2.2.2 Accuracy assessment on a renal cell carcinoma and its metastasis 
We also benchmarked DENDRO against existing methods on the renal cell carcinoma dataset 
from Kim et al [21] (Fig. 1.3). This dataset contained 116 cells sequenced using the Smart-seq 
technology [17], obtained from three tumors derived from one patient: a patient-derived xenograft 
(PDX) from the primary renal cell carcinoma (PDX_pRCC), a biopsy of the metastasis to the lung 
1 year after treatment of primary site (Pt_mRCC), and a PDX of the lung metastasis renal cell 
carcinoma (PDX_mRCC) (Fig. 1.6a). The cells should share common early driver mutations due 
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to their shared origin from the same patient, but the metastasis and the cultivation of each tumor 
in separate medium (human or mouse) should have allowed for the accumulation of new 
mutations. Thus, we expect the three tumors to be clonally distinct. This knowledge allows us to 
use this dataset to benchmark accuracy and to illustrate how DENDRO enables joint analysis of 
the genetic and transcriptomic heterogeneity at single cell resolution.  
GATK detected 2,867,029 mutation sites across all cells [1]. Mutations that are detected 
in less than 5% (too rare) or more than 95% (too common) of the cells were removed, which 
leaves 72,206 mutations. On average, 10801 mutations are detected in each cell and 17.35 cells 
possess the same mutation for each loci (Fig. 1.6b, c). For majority sites, only few cells have 
nonzero read coverage, highlighting the fact that many mutations are missed due to technical and 
biological dropout (Fig. 1.6d) [2-6]. 
We compared 4 different clustering methods: (1) DENDRO, (2) hierarchical clustering 
based on the primary genotype matrix 𝑍 generated by GATK ( 𝑍𝑐𝑔 = 1 when a mutation 𝑔 is 
detected for cell 𝑐, 𝑍𝑐𝑔 = 0 otherwise), (3) hierarchical clustering based on the 
𝑋
𝑁
 matrix that 
preserve the variant allele frequency information and (4) hierarchical clustering based on gene 
expression (log 𝑇𝑃𝑀). DENDRO gives the cleanest separation between the three populations with 
adjusted Rand Index of 0.932 (1.0 indicates perfect clustering, Fig. 1.3c panel 1), as compared to 
0.754 for Z matrix (Fig. 1.3c panel 2), 0.519 for 
𝑋
𝑁
 matrix (Fig. 1.3c panel 3) and 0.489 for 
expression (Fig. 1.3c panel 4). Inspection of the tree shows that, as expected, divergence 
between primary tumor and metastasis exceeds divergence between patient sample and PDX 
sample, as PDX_mRCC clusters with Pt_mRCC rather than PDX_pRCC. All of the other three 
methods successfully separated the primary sample from the metastatic samples, but could not 
differentiate between the two metastasis samples.  
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For DENDRO, the intra-cluster divergence curve flattened at 3, and thus we stopped 
splitting at 3 clusters (Fig. 1.6e and Methods). We annotated the clusters as PDX_mRCC, 
PDX_pRCC and Pt_mRCC by their cell compositions (Table 1.1a). DENDRO found minimal 
sharing of subclones among the tumors derived from three sources, and low genetic 
heterogeneity within each tumor. This is unsurprising since relapsed metastasis consists of cells 
that have already undergone selection, and since the PDX tumors are each seeded by a small 
subsample of cells from the original tumor, each tumor consists of unique subclones not detected 
in other sites [44-46].  
DENDRO enables simultaneous clonal assignment and transcriptomic profiling of the 
same set of cells. Plot of smoothed expression ordered by DENDRO shows unique expression 
patterns within each subclone (Fig. 1.7). We focused on the comparison of the two metastasized 
cell populations (metastasis to lung and patient derived mouse xenograph). Even though 
PDX_mRCC was derived from Pt_mRCC, the DENDRO analysis found substantial genetic 
divergence between the two cell populations. To investigate further, we performed a differential 
expression analysis between PDX_mRCC and Pt_mRCC with scDD and MAST, detecting 74 
significant differentially expressed genes (Methods, Fig. 1.8e, Table 1.2) [44-46]. Gene ontology 
analysis classified these 74 genes into two subgroups: immune-related genes and cancer-related 
genes (Table 1.3) [47]. Immune-related differentially expressed genes are enriched for the terms 
TNF-α signaling, complement system and allograft rejection. On the other hand, cancer related 
differentially expressed genes overlap with the pathways including hypoxia, KRAS signaling, 
mTORC1 signaling and epithelial mesenchymal transition.  
Simultaneously, we compare the mutation profiles of these two subclones. 9521 locus 
have different mutated allele counts between these two populations and were further annotated 
by ANNOVAR [48]. After filtering, the preserved variants associated with 24 out of 74 differential 
expressed genes (Table 1.2). Next, we performed a similar GSEA on variants associated genes 
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to identify mutation-related pathway [47]. Interestingly, variant annotated genes are enriched in 
cancer-related pathways, including mitotic spindle, mTORC1 signaling, EMT and hypoxia, 
overlapping substantially with the cancer-related pathways identified by differential expression 
analysis; in comparison, none of the differentially expressed genes from immune pathways 
showed up in this mutated gene analysis (Table 1.4). In another word, cancer-related 
transcriptomic divergence between PDX_mRCC and Pt_mRCC is driven directly by genetic 
alterations in the same genes, but immune-related differential expression is influenced by non-
DNA factors. This makes sense, since implantation of tumor cells from human to mice alters their 
immune microenvironment [49-51], and thus is expected to alter immune-related signaling within 
the implanted tumor cells. This illustrates how DENDRO extricates DNA variation from RNAs 
allowing their joint analysis. Differential expression and differential mutation analysis for the other 
subclone pairs can be found in Fig. 1.8. 
1.2.3 DENDRO analysis of melanoma model in response to immune checkpoint 
blockade highlights the role of neoantigens 
Immune checkpoint blockade (ICB) of the inhibitory receptors CTLA4 and PD1 can result in 
durable responses in multiple cancer types [47]. Features intrinsic to cancer cells that can impact 
ICB treatment outcome include their repertoire of neoantigens [48], tumor mutational burden 
(TMB) [49], and expression of PDL1 [50].  DENDRO analysis of scRNA-seq data allows joint 
DNA-RNA analysis of single cells, thus enabling the simultaneous quantification of tumor 
mutational burden, the prediction of neoantigen repertoire, and the characterization of gene 
expression profile at subclonal resolution. Thus, to demonstrate the power of DENDRO and to 
better understand the relationship between ICB response and intratumor heterogeneity, we 
profiled the single cell transcriptomes across three conditions derived from 2 melanoma cell lines 
(Fig. 1.9a): B16 melanoma cell line, which has shown modest initial response to ICB treatment 
but eventually grows out, and Res 499 melanoma cell line (R499), which was derived from a 
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relapsed B16 tumor after combined treatment of radiation and anti-CTLA4 and is fully resistant to 
ICB [51].  B16 was evaluated with and without anti-PD1 treatment, as we wanted a tumor model 
that captures a transient ICB response. A total of 600 tumor cells were sequenced with Smart-seq 
technology from six mice across three conditions: two mice with B16 without treatment (B16), two 
mice with B16 after anti-PD1 treatment (B16PD1) and two mice with R499 without treatment 
(R499) (Fig. 1.9a and Methods). The existence of multiple subclones in B16 and R499 was 
suggested by bulk WES analysis [51, 52]. Our goal here is to determine whether the subclones 
differ in anti-PD1 response, and if so, what are the subclonal differences.  
A DENDRO analysis of 4059 putative mutation sites across 460 cells retained after QC 
(see Methods and Fig. 1.10a, b, c) yields the clustering displayed in Fig. 1.9b, with four subclones 
suggested by the intra-cluster divergence curve (Fig. 1.10d).  All subclones are shared among the 
three conditions, which is not unexpected given that all tumor cells were derived from the same 
parental cell line.  However, the sub-clonal proportions vary significantly between conditions (Fig. 
1.9b).  The subclonal proportions of B16PD1 are approximately intermediate between that of B16 
and R499 (Fig. 1.9c). This is expected as R499 had gone through immune editing whereas 
B16PD1, at the time of harvest, was still undergoing immune editing and was at the transient 
response state. Furthermore, the selective pressure of radiation plus anti-CTLA4 is likely more 
than that of anti-PD1 treatment, as the former but not the latter results in complete responses in 
our B16 model [51]. The frequency of Clone 2 is lower in B16PD1 and R499, indicating sensitivity 
to anti-PD1 treatment, while the frequencies of Clone 3 and Clone 4 increase after treatment and 
are the highest in R499, indicating resistance to therapy (Fig. 1.9c, 1.11a).  
To explore why subclones vary in sensitivity to anti-PD1 treatment, we compared the 
mutation profile of Clone 2 to the other subclones. We pooled cells in each of the four subclones 
and re-estimated their mutation profiles, which were then used to construct a phylogenetic tree 
(Fig. 1.9d). The phylogeny suggests that Clone 3 and Clone 4 are genetically closer to each other 
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than to Clone 2, and thus, their similarity in treatment response may be in part due to similarity in 
their mutation profiles. The re-estimated mutation profiles show that Clone 2 has the highest 
tumor mutation burden, which has been associated with increased likelihood of ICB response [53, 
54]. We then predicted the quantity of high-affinity (≤ 100 nm) neoantigens in each subclone 
given its mutation profile [52]. As shown in Fig. 1.9e, Clone 2 has twice as many high-affinity 
neoantigens as the other three subclones. The high level of neoantigens can lead to better T cell 
recognition, resulting in increased efficacy of anti-PD1 treatment [55].  
Analysis of gene expression, on the other hand, did not yield detectable known 
signatures associated with anti-PD1 treatment sensitivity. Projections based on the expression of 
highly variable genes, as shown in PCA and t-SNE plots (Fig. 1.12), did not yield meaningful 
clusters. Differential expression analysis between each subclone and the other subclones found 
few genes with adjusted P-value < 0.05, indicating similar expression across sub-clones that is 
concordant with the lack of structure in the expression PCA and tSNE plots. Expressions of Pdl1 
(aka. Cd274) showed no differences between subclones (KS-test: P-value > 0.42, Fig. 1.11b). In 
addition, there were no detectable chromosome-level differences in smoothed gene expression, 
indicating that there are no large CNV events that distinguish the subclones (Fig. 1.13). 
DENDRO, detecting exonic mutations from scRNA-seq data, enabled the finding of subclones in 
this data, the prediction of neoantigen load of each subclone, and the analysis of subclonal 
dynamics due to treatment. Our analysis suggests that the genetic heterogeneity, rather than 
transcriptomic heterogeneity, contributes to treatment efficacy in this tumor model.  
1.2.4 Simultaneous analysis of genetic and transcriptomic variation in single cell breast 
cancer 
We next applied DENDRO to the analysis of data from a study of primary and metastasized 
breast cancer [20]. We focused on tumors from two patients (BC03 and BC09) that had the most 
cells sequenced (Fig. 1.14 and Table 1.5). Patient BC03 had cells sequenced from the primary 
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tumor (here after BC03P) as well as cells from regional metastatic lymph nodes (here after 
BC03LN), whereas patient BC09 had cells sequenced only from the primary resection. 132 single 
cell transcriptomes were profiled by Smart-seq protocol [17]. We first assess whether DENDRO 
separated BC03 cells from BC09 cells, since inter-individual genetic distances should far exceed 
intra-individual genetic distances owning to the randomness of passenger mutations [19, 22, 56] . 
Then, we examine the transcriptomic and genetic heterogeneity within each tumor.  
GATK [57] detected a total of 2,364,823 mutation sites across the 132 cells, 353,647 
passed QC (Methods) and were retained for downstream analysis (Fig. 1.14a, b, c). Fig. 1.15 
shows the clustering determined by DENDRO. DENDRO separates BC09 cells from BC03 cells 
with 100% accuracy (Fig. 1.15a). The intra-cluster divergence curve flattened at five subclones: 
three subclones for BC03 and two for BC09 (Fig. 1.15a, Fig. 1.14d and Table 1.1b). Within BC03, 
Clone Mix_1 and Clone Mix_2 contained a mixture of cells from the primary tumor and lymph 
nodes, and Clone LN_1 contained mostly cells from the lymph nodes. This suggests that tumor 
cells that have metastasized to the lymph nodes belong to an intermediate stage and are 
genetically heterogeneous, with some cells remaining genetically similar to the primary population 
and others acquiring new genetic mutations, coherent with previous studies [58, 59]. In 
comparison, hierarchical clustering based on expression (using log transcripts-per-million values) 
did not separate BC03 from BC09, and gave a negative adjusted Rand index within BC03, 
indicating effectively random assignment of cells to the two patients (Fig. 1.15b). 
We then pooled cells within each of the 5 clusters and re-estimated their mutation profiles 
with DENDRO. We defined a variant as subclonal if it was not present in all of the subclones 
within a tumor. Based on detection marginal likelihood, we picked the top 10,000 most confident 
variants to construct a phylogenetic tree (Fig. 1.15c). As expected, the two BC09 clusters are far 
from the three BC03 clusters. Within BC03, the length of the branches shows that the subclone 
containing mostly cells from lymph nodes (labeled BC03LN_1) is genetically more similar to 
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Clone Mix_2 compared to Clone Mix_1 (Fig. 1.15c). In addition, window-smoothed expression 
plot with cells grouped by DENDRO clustering shows broad chromosome-level shifts in 
expression patterns between subclones, most likely due to copy number aberrations that are 
consistent with SNAs (Fig. 1.16) [22]. 
A comparison of the transcriptomes of the subclones revealed substantial differences in 
the expression of PAM50 genes, which are prognostic markers for breast cancer (Fig. 1.15d) [60]. 
DENDRO detected one rare subclone, BC09_2, with only six cells (<5% of the total number of 
cells) which had a strong basal-like signature. Interestingly, in BC03, Clone LN_1 has the 
TNBC/basal-like subtype with an invasive gene signature, while Clone Mix_2 has the ESR1+ 
subtype. Thus, the genetic divergence of Clone LN_1 from Clone Mix_2 is accompanied by its 
acquisition of an invasive metastatic expression signature. In a direct comparison between cells 
from the primary site and cells from the lymph node without distinguishing subclones, these 
expression differences would be much weaker since the subclones do not cleanly separate by 
site. Compared with the original analysis that assigned each tumor to one specific breast cancer 
subtype, this analysis identifies subclones with different expression phenotypes, potentially 
allowing for better therapy design that targets all subclone phenotypes to reduce the risk of tumor 
relapse. 
Existing scRNA-seq studies of cancer tissue cluster cells based on total gene expression 
or copy number profiles derived from smoothed total expression, making it difficult to separate the 
effects of sub-clonal copy number aberrations from transcriptomic variation [19, 22, 24].  
Differential expression analysis based on clusters derived from total expression is prone to self-
fulfilling prophecy, as there would indeed be differentially expressed genes because this is the 
clustering criteria. Because DENDRO’s subclone identification is based solely on genetic 
divergence, and not on expression profile, the downstream differential gene expression analysis 
can be precisely attributed to transcriptional divergence between subclones. 
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Hence, we conducted a transcriptome-wide search for pathways that have differential 
expression between subclones (Methods and Table 1.6), and assessed their overlap with 
pathways that are differentially mutated between subclones. Focusing on tumor BC03, pathways 
for G2M checkpoint and KRAS signaling are up-regulated in lymph node metastasis Clone 
BC03LN_1, while pathways for estrogen response and apoptosis are down-regulated, indicating 
a more invasive phenotype. In addition, GAPDH is up-regulated in the metastatic subclone 
(BC03LN_1) and down-regulated in the two mix-cell subclones, consistent with previous findings 
[61, 62] (Fig. 1.17d). Differentially expressed genes between other subclone pairs in BC03 are 
also enriched in estrogen response, apoptosis, and DNA repair. In parallel, subclone-specific 
mutated genes are highly enriched in cancer-related pathways including MYC target, G2M 
checkpoints and mitotic spindle, and immune related pathways such as, interferon response, 
TNF-a signaling and inflammatory response (Table 1.6). Interestingly, few of the differentially 
mutated genes are associated with estrogen and androgen responses, suggesting that the 
differential expression of hormone related genes is not mediated directly by genetic mutations in 
these pathways. This is consistent with the recent studies that epigenetic alteration, such as 
histone acetylation and methylation, regulate hormones receptor signaling in breast cancer [63-
66]. DNA-RNA joint analysis between other subclones are included in Fig. 1.17. Overall, this 
example illustrates how DENDRO enables the joint assessment of genetic and transcriptomic 
contributions to clonal diversity at single-cell resolution. 
 Discussion 
We have described DENDRO, a statistical framework to reconstruct intratumor DNA-level 
heterogeneity using scRNA-seq data. DENDRO starts with mutations detected directly from the 
scRNA-seq reads, which are very noisy due to a combination of factors: (1) errors are introduced 
in reverse-transcription, sequencing and mapping, (2) low sequencing depth and low molecule 
conversion efficiency leading to technical dropouts, and (3) expression burstiness at the single 
cell level leading to biological dropouts. DENDRO overcomes these obstacles through the 
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statistical modeling of each component. Given noisy mutation profiles and allele-specific read 
counts, DENDRO computes a distance between each pair of cells that quantifies their genetic 
divergence after accounting for transcriptional bursting, dropout and sequencing error. Then, 
DENDRO clusters the cells based on this distance as subclone and re-estimates a more robust 
subclone-specific mutation profile by pooling reads across cells within the same cluster. These re-
estimated mutations profiles are then passed to downstream mutation analysis and phylogenetic 
tree reconstruction. 
Importantly, the genetic divergence used by DENDRO for cell clustering is based solely 
on allelic expression ratios and do not reflect the difference in total expression between cells at 
mutation sites. Thus, DENDRO differs from, and complements, existing tools that cluster cells 
based on total expression. In fact, as shown by simulation analysis, DENDRO clusters the cells 
based on true underlining mutation profiles, and is robust to changes in total gene expression. As 
expected, the numbers of cells, the depth of sequencing, the actual number of subclonal 
mutations and the phylogenetic tree structure all influence the power of DENDRO. To aid 
researchers in experiment design, we developed DENDROplan, which predicts DENDRO’s 
clustering accuracy given basic experimental parameters and the expected informative mutation 
count, which can be obtained from bulk DNA sequencing.  
Ideally, joint sequencing of the DNA and RNA on the same cells would allow us to relate 
genomic profiles to transcriptomic variations. Currently, there is yet no scalable technology for 
doing this. Separately performing scDNA-seq and scRNA-seq on different batches of cells within 
the same tumor would meet the nontrivial challenge of matching the subclones between the two 
data sets. DENDRO takes advantage of the central dogma and utilizes computational methods to 
extract genetic divergence information from noisy mutation calls in coding regions. Through two 
case studies, we illustrate the insights gained from the subclonal mutation and expression joint 
analysis that DENDRO enables.  
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We have demonstrated that proper computational modeling can excavate the DNA-level 
heterogeneity in scRNA-seq data. Yet, there are always limitations in working with RNA. While 
rare RNA editing events are absorbed by the parameter 𝜖, DENDRO cannot distinguish subclone-
specific constituent RNA editing events from subclone-specific DNA mutations. In the extreme 
and unlikely scenario where RNA editing events are common and pervasive, DENDRO’s cluster 
would reflect RNA editing. In such cases, we recommend using matched bulk DNA-seq of the 
same tumor to filter the loci detected in the first step of DENDRO, keeping only those that are 
supported by at least one read in the bulk DNA-seq data. In addition, DENDRO’s analysis is 
restricted to transcribed regions, as variants are detected using transcriptomic data, and thus 
ignores non-coding mutations which can sometimes be informative for tumor evolution [67-70].  
Tag-based scRNA-seq (10X, Drop-seq, etc.) is now commonly adopted for cancer 
sequencing, but we do not recommend applying DENDRO to this sequencing design because of 
two reasons: (1) limited number of variants can be detected with tag-based methods as they only 
profile a small fraction of the transcript (3-prime or 5-prime end); and (2) the sequencing depth of 
tag-based methods are critically low (<0.1X), resulting in unreliable variant calling.  However, we 
do anticipate that emerging technologies, such as long-read full-transcript scRNA-seq 
technologies [71] and transcriptome-based deep targeted sequencing [31, 32] will overcome 
these limitations of tag-based scRNA-seq. Given proper experimental design, we expect that 
these emerging technologies will be ideally suited for the joint analysis of exonic somatic 
mutations and gene expression. 
 Methods 
1.4.1 scRNA-seq alignment and SNA calling pipeline 
Fig. 1.2 illustrates the SNA calling pipeline. Raw scRNA-seq data is aligned by STAR 2-
pass method (default parameters), which accounts for splicing junctions and achieve higher 
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mapping quality [72]. Transcripts per million (TPM) was quantified using RSEM (default 
parameters) [73]. In the next step, raw variants calling is made using the Haplotype Caller (GATK 
tool) on the BAM files after sorting, joining read groups, removing duplicated reads, removing 
overhangs into intronic regions, realigning and recalibration [74]. Conventionally, there are two 
methods from GATK tools for mutation detection: haplotype caller and mutect2. Haplotype caller 
has a RNA-seq setting which handle splice junctions correctly, but assumes VAF around 50%, 
while mutect2 can detect mutations with low VAF but does not account for splice junction. The 
reason we select haplotype caller instead of mutect2 is that we extract allele read counts for all 
cells as long as one of the cells is listed as carrying the mutation. Thus, as long as one cell has 
VAF reaching 50%, this mutation would be detected. Calls with stand_call_conf greater than 20 
and population frequency greater than 5% but less than 95% were preserved for further analysis. 
Admittedly, such lenient filtering typically introduces false positive sites. However, our priority at 
this step is to minimize false negative rate, while the genetic divergence matrix in the following 
step robustly estimates cell population substructure. Both the coverage of the alternative allele 
and the total read coverage are extracted for each site for further analysis.  
1.4.2 Data preprocessing and quality control 
To ensure robustness of downstream analysis, we filtered out low quality cells, variants and 
genes. We retained: Cells with (1) >10000 reads mapped, (2) <10% mitochondria gene 
expression and (3) >1000 gene detected; genes with > 5 cells detected (TPM>0 as detected); 
and variants with > 2 cells detected by GATK.  Original TPM values as defined by RSEM were 




1.4.3 Genetic Divergence and Beta-Binomial framework 
Consider two cells: 𝑐 and 𝑐’. Let 𝐼𝑐 and 𝐼𝑐′ denote the clonal group to which the cells belong, i.e. 
𝐼𝑐 =  𝐼𝑐′ if and only if cells 𝑐 and 𝑐’ come from the same subclone. We define the genetic 
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where 𝑋𝑐 = (𝑋𝑐1, 𝑋𝑐2, … 𝑋𝑐𝑔 , … 𝑋𝑐𝑚) are the mutation allele read counts for cell 𝑐 and 𝑁𝑐 =
(𝑁𝑐1, 𝑁𝑐2, … 𝑁𝑐𝑔 , … 𝑁𝑐𝑚) are the total read counts at these sites. More intuitively, if cells 𝑐 and 𝑐′ are 
not from the same clonal group, the probability of cell cells 𝑐 and 𝑐′ from the same cells given 
data (i.e. denominator) has smaller value. Thus 𝑑𝑐𝑐′
𝑔
 is large, indicating bigger divergence 
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𝑃(𝑋𝑐𝑔, 𝑋𝑐′𝑔|𝑁𝑐𝑔 , 𝑁𝑐′𝑔 , 𝐼𝑐 ≠ 𝐼𝑐′)
𝑃(𝑋𝑐𝑔, 𝑋𝑐′𝑔|𝑁𝑐𝑔 , 𝑁𝑐′𝑔 , 𝐼𝑐 = 𝐼𝑐′)
+ 1) 
where 𝐷𝑐 = {(𝑁𝑐1, 𝑁𝑐2, … 𝑁𝑐𝑔, … 𝑁𝑐𝑚), (𝑋𝑐1, 𝑋𝑐2 , … 𝑋𝑐𝑔 , … 𝑋𝑐𝑚) are data for cell 𝑐. 
𝑃(𝑋𝑐𝑔,𝑋𝑐′𝑔|𝑁𝑐𝑔,𝑁𝑐′𝑔,𝐼𝑐≠𝐼𝑐′)
𝑃(𝑋𝑐𝑔,𝑋𝑐′𝑔|𝑁𝑐𝑔,𝑁𝑐′𝑔,𝐼𝑐=𝐼𝑐′)
 could also be called a Bayes Factor. More intuitively, if cell 𝑐 and 𝑐′ are not 
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from the same clonal group, the numerator has larger value compared to denominator. Thus, 𝑑𝑐𝑐′
𝑔
 
is large, indicating bigger divergence between the two cells. 
To further expand the formula, let us focus on the denominator first: 
𝑃(𝑋𝑐𝑔 , 𝑋𝑐′𝑔 |𝑁𝑐𝑔, 𝑁𝑐′𝑔 , 𝐼𝑐 = 𝐼𝑐′)  
= 𝑃(𝑋𝑐𝑔 , 𝑋𝑐′𝑔 |𝑁𝑐𝑔 , 𝑁𝑐′𝑔 , 𝑍𝑐𝑔 = 𝑍𝑐′𝑔 = 0 )𝑃(𝑍𝑐𝑔 = 𝑍𝑐′𝑔 = 0|𝐼𝑐𝑔 = 𝐼𝑐′𝑔)
+ 𝑃(𝑋𝑐𝑔, 𝑋𝑐′𝑔 |𝑁𝑐𝑔 , 𝑁𝑐′𝑔 , 𝑍𝑐𝑔 = 𝑍𝑐′𝑔 = 1 )𝑃(𝑍𝑐𝑔 = 𝑍𝑐′𝑔 = 1|𝐼𝑐𝑔 = 𝐼𝑐′𝑔) 
= 𝑃(𝑋𝑐𝑔 |𝑁𝑐𝑔 ,  𝑍𝑐𝑔 = 0)𝑃(𝑋𝑐′𝑔 |𝑁𝑐′𝑔 ,  𝑍𝑐′𝑔 = 0)(1 − 𝑃𝑔)
+ 𝑃(𝑋𝑐𝑔 |𝑁𝑐𝑔 ,  𝑍𝑐𝑔 = 1)𝑃(𝑋𝑐′𝑔 |𝑁𝑐′𝑔,  𝑍𝑐′𝑔 = 1)𝑃𝑔 
where 𝑃𝑔 = 𝑃(𝑍𝑔 = 1) indicates the population mutation frequency in the group of cells, estimated 
from GATK calling; and 𝑃(𝑍𝑔 = 0) = 1 − 𝑃(𝑍𝑔 = 1) = 1 − 𝑃𝑔 . 
Then the numerator: 
𝑃(𝑋𝑐𝑔 , 𝑋𝑐′𝑔 |𝑁𝑐𝑔 , 𝑁𝑐′𝑔 , 𝐼𝑐 ≠ 𝐼𝑐′) 
= 𝑃(𝑋𝑐𝑔 , 𝑋𝑐′𝑔 |𝑁𝑐𝑔 , 𝑁𝑐′𝑔 , 𝑍𝑐𝑔 = 0,  𝑍𝑐′𝑔 = 0 )𝑃(𝑍𝑐𝑔 = 0, 𝑍𝑐′𝑔 = 0|𝐼𝑐𝑔 ≠ 𝐼𝑐′𝑔)
+ 𝑃(𝑋𝑐𝑔, 𝑋𝑐′𝑔 |𝑁𝑐𝑔 , 𝑁𝑐′𝑔 , 𝑍𝑐𝑔 = 1,  𝑍𝑐′𝑔 = 1 )𝑃(𝑍𝑐𝑔 = 1, 𝑍𝑐′𝑔 = 1|𝐼𝑐𝑔 ≠ 𝐼𝑐′𝑔)
+ 𝑃(𝑋𝑐𝑔, 𝑋𝑐′𝑔 |𝑁𝑐𝑔 , 𝑁𝑐′𝑔 , 𝑍𝑐𝑔 = 0,  𝑍𝑐′𝑔 = 1 )𝑃(𝑍𝑐𝑔 = 0, 𝑍𝑐′𝑔 = 1|𝐼𝑐𝑔 ≠ 𝐼𝑐′𝑔)
+ 𝑃(𝑋𝑐𝑔, 𝑋𝑐′𝑔 |𝑁𝑐𝑔 , 𝑁𝑐′𝑔 , 𝑍𝑐𝑔 = 1,  𝑍𝑐′𝑔 = 0 )𝑃(𝑍𝑐𝑔 = 1, 𝑍𝑐′𝑔 = 0|𝐼𝑐𝑔 ≠ 𝐼𝑐′𝑔) 
= 𝑃(𝑋𝑐𝑔 |𝑁𝑐𝑔 ,  𝑍𝑐𝑔 = 1)𝑃(𝑋𝑐′𝑔 |𝑁𝑐′𝑔 ,  𝑍𝑐′𝑔 = 0)(1 − 𝑃𝑔)𝑃𝑔
+ 𝑃(𝑋𝑐𝑔 |𝑁𝑐𝑔,  𝑍𝑐𝑔 = 0)𝑃(𝑋𝑐′𝑔 |𝑁𝑐′𝑔,  𝑍𝑐′𝑔 = 0)(1 − 𝑃𝑔)
2
+ 𝑃(𝑋𝑐𝑔 |𝑁𝑐𝑔,  𝑍𝑐𝑔 = 1)𝑃(𝑋𝑐′𝑔 |𝑁𝑐′𝑔,  𝑍𝑐′𝑔 = 1)𝑃𝑔
2
+ 𝑃(𝑋𝑐𝑔 |𝑁𝑐𝑔,  𝑍𝑐𝑔 = 0)𝑃(𝑋𝑐′𝑔 |𝑁𝑐′𝑔,  𝑍𝑐′𝑔 = 1)(1 − 𝑃𝑔)𝑃𝑔 
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As a result, 𝑑𝑐𝑐′
𝑔
 is a function of the five following probabilities:  
𝑑𝑐𝑐′
𝑔
= 𝑓 (𝑃𝑔; 𝑃(𝑋𝑐𝑔|𝑁𝑐𝑔, 𝑍𝑐𝑔 = 0); 𝑃(𝑋𝑐𝑔|𝑁𝑐𝑔 , 𝑍𝑐𝑔 = 1); 𝑃(𝑋𝑐′𝑔|𝑁𝑐′𝑔, 𝑍𝑐′𝑔 = 0); 𝑃(𝑋𝑐′𝑔|𝑁𝑐′𝑔 , 𝑍𝑐′𝑔 = 1)) 
where 𝑍𝑐𝑔 ∈ {0,1} is SNA indicator for cell 𝑐 at site 𝑔 and 𝑃𝑔 = 𝑃(𝑍𝑔 = 1) is mutation frequency 
across the cells estimated by GATK calls.  
In the above formula for 𝑑
𝑐𝑐′
𝑔
, 𝑃(𝑋𝑐𝑔|𝑁𝑐𝑔 , 𝑍𝑐𝑔 = 0) and 𝑃(𝑋𝑐′𝑔|𝑁𝑐′𝑔 , 𝑍𝑐′𝑔 = 0) reflect 
reverse-transcription/sequencing/mapping errors and rare RNA editing events, because when 
there is no mutation (i.e. 𝑍𝑐𝑔 = 0, 𝑍𝑐′𝑔 = 0), all mutation reads reflect such technical errors or RNA 
editing. Let 𝜖 denote the combined rate of technical error and RNA editing, we have 
𝑃(𝑋𝑐𝑔|𝑁𝑐𝑔 , 𝑍𝑐𝑔 = 0)~Binomial(𝑋𝑐𝑔|𝑁𝑐𝑔, 𝜖) 
where 𝜖 is set to 0.001 based on prior knowledge {Pfeiffer, 2018 #411}. 
For cases where there are mutations (i.e. 𝑍𝑐𝑔 = 1), the distribution of mutated read 
counts given total read counts is modeled with a Beta Binomial distribution, which is capable of 
modeling technical dropout and transcriptional bursting, and is supported by previous allele 
specific expression studies [34, 75] . 




𝑞 ∼ Beta(𝛼𝑔, 𝛽𝑔) 
where 𝑄𝑐𝑔 indicates proportion of mutated alleles expressed in cell 𝑐 at site 𝑔, with Beta 
distribution as prior. Respectively, 𝛼𝑔 and 𝛽𝑔 represent gene activation and deactivation rate, 
which are estimated empirically across cells based on first and second moment estimator.  
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Through optimized vectorization, given a data set of 500 cells with 2500 variants, genetic 
divergence matrix can be computed under 2 mins in a normal desktop with 16GB of RAM (single 
thread). Analytically, the algorithm is of complexity 𝑂(𝑁2 ∗ 𝐺), where 𝑁 is number of cells and 𝐺 is 
number of variants. 
1.4.4 Kernel based clustering and optimal cluster assignment 
We cluster the cells using a kernel-based algorithm, such as hierarchical clustering. Given that 
there are multiple sorting schemes, we leave the user to choose it. For the default-sorting 
scheme, we recommend “ward.D” [76]. This is because 𝑑𝑐𝑐′ behaves like a log likelihood ratio, 
which should follow a 𝜒2 distribution when the two cells share the same subclone. The “ward.D” 
method has been shown to work well in Euclidian space. Empirically, among different hierarchical 
clustering algorithms on the renal cell carcinoma dataset (Fig. 1.18) “ward.D” based hierarchical 
clustering performs the best. 
To determine the number of clusters we use an intra-cluster divergence curve computed 
from the divergence matrix. Existing software rely on AIC, BIC, or another model selection metric 
[77, 78]. However, since we only have the “distance” matrix, these traditional methods cannot be 
applied. Let 𝑁𝑘 be the number of cell pairs in cluster 𝐶𝑘 and 𝑁 be the total number of pairs 
between cells for all clusters. Let 𝐾 be the number of clusters.  The weighted sum of intra-cluster 
distance 𝑊𝐾 is 







Note that small clusters are naturally down-weighted in the above metric.  DENDRO 
relies on visual examination of the intra-cluster divergence curve (𝑊𝐾 plotted against 𝐾) to find 
the “elbow point”, which can be taken as a reasonable clustering resolution. 
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1.4.5 Simulation analysis 
In our simulation analysis, we adopt a scRNA-seq dataset from Deng et al. as the reference, 
which, by crossing two mouse strains, obtained transcriptomic allele specific read counts for 
every SNPs in exonic regions in each cell [43]. In this case, the Deng et al. data maintained the 
expression stochasticity in scRNA-seq data. To overlay the read counts on simulated mutation 
profile, for every simulated locus, we sampled a SNP from this reference. For cells with mutation 
at this locus, we randomly assigned one allele of the sampled SNP as mutated allele. For cells 
without mutation, we set the mutated allele counts as 0 and the total read counts as sum of the 
two alleles from the reference. We further added binomial noise (𝑝𝜖 = 0.001, suggested by [79]) 
to mimic sequencing error. When analyzing DENDRO performance in terms of various number of 
mutation sites, number of cells, proportion of cells in each clade and proportion of mutations 
along each branch, we only take a subset of cells (cells in early blastocyst, mid blastocyst and 
late blastocyst stages) to ensure the expression homogeneity. On the other hand, we utilize a 
mixture cell population (cells in 16-cell stages and blastocyst stages) to test the robustness of 
DENDRO performance with regard to various expression profiles.  
1.4.6 Power analysis toolkit and experimental design 
Before conducting a single cell RNA-seq experiment on a tumor sample, it is important to project 
how subclone detection power depends on the number of cells sequenced and the coverage per 
cell. To facilitate experiment design, we have developed a tool, DENDROplan (Fig. 1.3a), that 
predicts the expected clustering accuracy by DENDRO given sequencing parameters and 
available bulk data for the tumor. Given an assumed tree structure and a target accuracy, 
DENDROplan computes the necessary read depth and number of cells needed.  
We evaluate DENDRO accuracy in DENDROplan with three different metrics: Adjusted 
Rand index, capture rate and purity. 
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1. Adjusted Rand index: Adjusted Rand index is a measure of the similarity between two 
data clusterings after adjusted for the chance grouping of elements. For details, see 
https://en.wikipedia.org/wiki/Rand_index 
2. Capture rate: Capture rate is a measure of “false negative rate” of a specific clade. Out of 
all the cells from the specific clade, how many of them is detected by the algorithm. 
3. Purity: Purity is a measure of “false positive rate” of a specific clade. Out of all the cells in 
the “specific cluster” you detected, how many are actually from the true specific clade. 
As shown in Fig. 1.3a, if bulk DNA sequencing and/or RNA sequencing data are available 
for the tumor being studied, these data can be harnessed to make more realistic power 
calculations. For example, if SNAs have been profiled using bulk DNA sequencing data, the set of 
mutations that lie in the exons of annotated genes can be retrieved and used directly in 
constructing the simulation data. Furthermore, phylogeny construction algorithms for bulk DNA-
seq data can be used to infer a putative tree structure that can be used as input to DENDROplan 
[5, 78]. If bulk RNA-seq data is available, the bulk expression level of the mutation-carrying genes 
can be used to predict the expression level of the mutation in the single cell data. In another 
word, variants in high-expressed genes in bulk will be sampled from high-expressed variant loci in 
scRNA reference and vice versa. The power analysis tool is also available at 
https://github.com/zhouzilu/DENDRO. 
1.4.7 SNA inference in “bulk” and phylogenetic tree construction 
As stated previously, DENDRO further inferred SNA after pooling the reads from all cells within 
each cluster. Because, with our choice of thresholds, we identify SNAs in single cells with high 
sensitivity, the “bulk” level SNAs should be a subset of the SNAs in single cells, and mutation 
allele counts and total allele counts should provide us with enough information for SNA detection 
using a maximum likelihood framework [80], which accounts for both sequencing error and rare 
25 
 
RNA-editing events. Suppose 𝑠 is the genotype (number of reference allele) at a site and assume 




∏[(𝑚 − 𝑠)𝜖 + 𝑠(1 − 𝜖)]
𝑙
𝑗=1




where 𝑘 is number of reads at a site and the first 𝑙 bases (𝑙 ≤ 𝑘) be the same to reference and the 
rests are same to alternative allele. 𝜖 is the sequencing error and rare RNA-editing combined 




Given mutation profiles, DENDRO then constructs a phylogenetic tree with the neighbor-
joining method, which can more accurately capture the evolutionary relationship between different 
subclones [81] than the initial tree given by hierarchical clustering. 
1.4.8 Differential gene expression, mutation annotation and gene ontology analysis 
We use Seurat and scDD to identify differentially expressed genes between tumors and between 
tumor subclones [82-84]. For each comparison, we apply two different methods: MAST 
implemented by Seurat and scDD. Genes with adjusted p-value < 0.05 count as significant 
differentially expressed gene for each method. We further intersect these two sets of differentially 
expressed genes to increase robustness. Subclonal mutations are annotated by ANNOVAR with 
default parameters and variants associated with intergenic regions were discarded for 
downstream analysis [85]. For GO analysis, we apply Gene Set Enrichment Analysis tool [57]. 
Hallmark gene sets serve as fundamental database with FDR q-value < 0.05 as significant.  
1.4.9 Single cell RNA-seq of Tumor Model Derived from B16 
Six C57bl/6 mice were injected on both flanks with either B16 or R499: four with B16 and two with 
R499. Two of the mice implanted with B16 were treated with 200 ug of anti-PD1 per mouse on 
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Days 5, 8 and 11. On Day 15, all tumors were harvested and made into single cell suspension. 
100,000 CD45 negative tumor cells were sorted on Aria to enrich for live tumor cells and loaded 
on SMARTer ICELL8 cx Single-Cell System prior to full length single cell RNA-sequencing library 
preparation using Smart-seq following manufacturer’s recommendations. 460 cells and 11531 
genes passed standard QC and were retained for downstream analysis. 
1.4.10 Neoantigen prediction 
Based on gene expression from RNA-seq data, variants from unexpressed transcripts are 
removed. The MHC-I binding affinities of variants are then predicted using NetMHC version 4.0 
for H-2-Kb and H-2-Db using peptide lengths from 8 to 11 [86]. Given subclonal mutation profile, 
we further assign the neoantigens to each subclone. 
1.4.11 Quantitative function analysis on genetic divergence evaluation by simulation 
Better understanding of the genetic divergence evaluation function is essential to DENDRO. 
Especially, we need to make sure DENDRO is capturing DNA level information from mutation 
rather than RNA level information from relative expression. This function, however, is quite 
complicated and difficult to analyze directly. As a result, we design several simulation schemes 
and analyze the function performance given different variables. 
Let’s consider 2 cells: cell 𝑐 and 𝑐’. We design true mutation profile 𝑍 (an indicator 




) at each position as Fig. 1.5.  







where 𝑚 is the total number of mutations. In another word, 𝑑𝑧 = 𝑝, which is the true mutation rate 
in cell 𝑐.  
We also define Δ = |𝐻 − 𝑀| = |𝑀 − 𝐿|, representing relative expression differences. 
Here, H, M and L represent high expression, medium expression and low expression 
respectively. 





= (1 − 𝑝)𝛥 
We further have genetic divergence, 𝑑𝐿, calculated by negative log likelihood in 
DENDRO. 
It is also interested in studying the relationship with 𝑁, the total number of read counts for 
each cell. 
In our simulation, we alter 𝛥, 𝑝 and 𝑁, assessing the responses in 𝑑𝐿 , 𝑑𝜃  and 𝑑𝑧. Results 
show that (1) our genetic divergence function is orthogonal to relative expression level (Fig. 1.5b). 
With fixed mutation rate 𝑝 and total read counts 𝑁, as relative expression differences 𝑑𝜃 
increases, 𝑑𝐿 stay constant; (2) When we keep relative expression differences 𝑑𝜃 and total read 
counts 𝑁 as constant, as number of true mutation (𝑑𝑧 or 𝑝) increases, genetic divergence 𝑑𝐿 also 
increases (Fig. 1.5c); and (3) genetic divergence 𝑑𝐿 monotonically increases with total expression 
level (𝑁) if we fix mutation distance 𝑑𝑧 (Fig. 1.5d). This can be interpreted that with more reads 
support, DENDRO is more confident that the two cells belong to different clusters. 
 Conclusions 
We have developed DENDRO, a statistical method for tumor phylogeny inference and clonal 
classification using scRNA-seq data. DENDRO accurately infers the phylogeny relating the cells 
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and assigns each single cell from the scRNA-seq data set to subclone. DENDRO allows us to (1) 
cluster cells based on genetic divergence while accounting for transcriptional bursting, technical 
dropout and sequencing error, as benchmarked by in silico mixture and a simulation analysis, (2) 
characterize the transcribed mutations for each subclone, and (3) perform single-cell multi-omics 
analysis by examining the relationship between transcriptomic variation and mutation profile with 
the same set of cells. We evaluate the performance of DENDRO through a simulation analysis 
and a data set with known subclonal structure. We further illustrate DENDRO through two case 
studies. In the first case study of relationship between intratumor heterogeneity and ICB 
treatment response, DENDRO estimates tumor mutation burden and predicts repertoire of high-
affinity neoantigens in each subclone from scRNA-seq. In the second case study on a primary 
breast tumor dataset, DENDRO brought forth new insights on the interplay between intratumor 
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transcriptomic variation and subclonal divergence. 
 
Figure 1.1 DENDRO analysis pipeline and genetic divergence evaluation. a DENDRO 
analysis pipeline overview. b, c Statistical model for genetic divergence evaluation function. b 
(top) Cell-level snapshots of the variant allele frequency (VAF) profiles for two genes with 
underlying differences in expression dynamics are shown. Gene 𝑔 is a bursty gene and 𝑔′ is a 
constitutive gene. (bottom) The stochasticity of gene expression is captured by the VAF 
distribution across all cells. c Although the observed read counts from two potential cells (𝑐1 and 
𝑐2) in the population are identical between the two loci, the genetic divergence computed from 
gene 𝑔 is less than that computed from gene 𝑔′ due to differences in transcriptional burstiness.  
DENDRO accounts for the full distribution of frequency profiles across cells when estimating the 




Figure 1.2 An illustration of the SNA calling pipeline. Raw scRNA-seq data is aligned by 





Figure 1.3 DENDRO accuracy assessment. a The overall simulation analysis pipeline. Mutation 
matrix (cell-by-loci) is generated according to a simulated evolutionary tree, where the leaves are 
subclones and mutations can be placed on the branches. Matrices of alternative allele (𝑋𝑐𝑔) and 
total read counts (𝑁𝑐𝑔) are sampled from a scRNA-seq dataset with known transcriptomic allele 
specific read counts. DENDRO cluster is further applied and its performance is assessed by 
adjusted Rand index (global accuracy), capture rate (subclone-specific sensitivity) and purity 
(subclone-specific precision). See Methods for detailed definition. Grey dashed line indicates 
optional input for DENDROplan, where bulk DNA-seq and bulk RNA-seq can guide the tree 
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simulation and read count sampling procedure. b Cluster accuracy via simulation studies. Various 
parameters show effects on cluster accuracy (measured by adjusted Rand index) based on tree 
structure on the most right. Left panel: effect of mutation burden on fixed read depth. Right panel: 
effect of read depth on fixed mutation burden. c Evaluation of DENDRO on a renal cell carcinoma 
and its metastasis. (Left to right) (1) DENDRO clustering result from primary and metastatic renal 
cell carcinoma dataset. Background colors represent DEDRO clustering result. (2) Clustering of 
the same dataset using 𝑍 matrix (indicator matrix, 𝑍𝑖𝑗 = 1 when detected a mutation for cell 𝑖 at 
locus 𝑗 by GATK tool). (3) Clustering of the same dataset using 
𝑋
𝑁
 matrix (mutation allele 




Figure 1.4 DENDRO accuracy assessment by simulation analysis. a Statistics under different 
SNV load of interested clade (i.e. as fraction of total mutation counts) in a pure cell population vs. 
a mixture of two cell types (50% each). b Statistics under different cell proportion of interested 
clade in a pure cell population vs. a mixture of two cell types (50% each). (Mutation counts: 
number of mutation identified; Avg mutation read depth: average read depth of all the mutation 
sites.) Both plots show that mixture of cell population does not affect accuracy. c DENDRO 
accuracy assessment in mixture cell types. d Clustering accuracy assessment using DENDRO 




Figure 1.5 Kernel function justification by simulation. a Illustration of simulation set up. b With 
fixed 𝑝 and 𝑁, as 𝑑𝜃 increases, 𝑑𝐿 stay constant. Thus, likelihood kernel is orthogonal to relative 
expression. c With fixed 𝑝 = 1, as 𝑁 approach infinite, 𝑑𝐿 increases monotonically. As there are 
higher expression, we are more confident that the two cells belong to different clusters. d When 





Figure 1.6 RCC experiment design and its mutation statistics detected by GATK tool. a 
Experimental design for renal cell carcinoma dataset. Figure modified from Kim et al. b Mutation 
count across cells by GATK. Most of the genes have low mutation frequency. c Mutation count 
across genes by GATK tool. It shows mutation counts with a bell shape. d NA percentage in each 
cell across genes. When there is no read counts, it shows as NA. e Intra-cluster divergence curve 
to select optimal number of cluster by DENDRO. Here, optK =3. f Phylogenetic tree of three cell 




Figure 1.7 Expression of renal cell carcinoma. a DENDRO clustering of RCC. b Smoothed 
expression ordered by DENDRO clustering. Vertical line separate cluster identified by DENDRO. 




Figure 1.8 Most significant differential expressed genes between RCC pairs. a PDX_mRCC 
vs. others. b PDX_pRCC vs. others. c Pt_mRCC vs. others. d PDX_mRCC vs. PDX_pRCC. e 




Figure 1.9 Clonal composition alternations with anti-PD1 treatments and cell lines. a 
Experimental overview. For each condition at Day 15, we have two biological replicates. There 
are total 600 cells from 6 tumors sequenced. b DENDRO cluster result. No clone is exclusively 
associated with any tumor condition. c Frequencies of the subclonal populations in B16, B16PD1 
and R499. d Neighbor joining phylogenetic tree given detected subclones. e Number of high 




Figure 1.10 Anti-PD1 treatment experiment mutation statistics detected by GATK tool and 
optimal clustering option. a NA percentage in each cell across genes. When there is no read 
counts, it shows as NA. b Mutation count across cells by GATK. Most of the genes have low 
mutation frequency. c Mutation count across genes by GATK tool. It shows mutation counts with 





Figure 1.11 Anti-PD1 treatment experiment. a Frequencies of the subclonal population in each 




Figure 1.12 Transcriptome analysis on anti-PD1 treatment experiment. a PCA plot of the cells 





Figure 1.13 Expression of anti-PD1 treatment experiment. a DENDRO clustering. Color 
indicates various conditions. b Smoothed expression heatmap ordered by DENDRO clustering. 





Figure 1.14 Breast cancer dataset mutation statistics detected by GATK tool and optimal 
clustering option. a NA percentage in each cell across genes. When there is no read counts, it 
shows as NA. b Mutation count across cells by GATK. Most of the genes have low mutation 
frequency. c Mutation count across genes by GATK tool. It shows mutation counts with a bell 





Figure 1.15 Analysis of scRNA-seq dataset of primary breast cancer. a DENDRO cluster 
result for primary breast cancer dataset (Chung et al., 2017). b Hierarchical clustering result for 
the same dataset based on expression (logTPM). (dashlines indicate cluster boundaries). c 
Neighbor joining phylogenetic tree given detected subclones for breast cancer dataset. d PAM50 




Figure 1.16 Expression of primary breast cancer. a DENDRO clustering of breast cancer. b 
Smoothed expression ordered by DENDRO clustering. Vertical line separate cluster identified by 




Figure 1.17 Most significant differential expressed genes between different BC pairs. a 
BC03 vs. BC09. b BC03Mix1 vs. BC03 others. c BC03Mix2 vs. BC03 others. d BC03LN1 vs. 




Figure 1.18 Hierarchical clustering algorithm comparison for renal cell carcinoma dataset. 








Table 1.1 a RCC subclone cell composition and labels. b BC subclone cell composition and 
labels. 
 a Cluster 1 Cluster 2 Cluster 3 
PDX_mRCC 36 0 0 
PDX_pRCC 0 46 0 
Pt_mRCC 3 0 31 
Final label PDX_mRCC PDX_pRCC Pt_mRCC 
b  Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5 
BC03 13 15 5 0 0 
BC03LN 7 9 32 0 0 
BC09 0 0 0 45 6 
Final label BC03Mix_1 BC03Mix_2 BC03LN_1 BC09_1 BC09_2 
 
Table 1.2 a Number of differential expressed gene between groups. b Number of differential 
expressed gene between groups overlapped with differential mutated genes (# of overlapped 
genes/# of differential expressed genes). 
a 
 PDX_mRCC PDX_pRCC Pt_mRCC Other 
PDX_mRCC  276 74 181 
PDX_pRCC 276  191 302 
Pt_mRCC 74 191  98 
Other 181 302 98  
b 
 PDX_mRCC PDX_pRCC Pt_mRCC Other 
PDX_mRCC  93/276 24/74 41/181 
PDX_pRCC 93/276  68/191 64/302 
Pt_mRCC 24/74 68/191  15/98 





Table 1.3 GO analysis on Differential Expressed Genes between Pt_mRCC and PDX_mRCC 









HALLMARK_TNFA_SIGNALING_VIA_NFKB [200] 1.86 e-8 9.28 e-7 
HALLMARK_HYPOXIA [200]* 5.04 e-7 1.26 e-5 
HALLMARK_MTORC1_SIGNALING [200]* 1.15 e-5 1.92 e-4 
HALLMARK_COMPLEMENT [200] 2.15 e-4 1.79 e-3 
HALLMARK_GLYCOLYSIS [200]* 2.15 e-4 1.79 e-3 
HALLMARK_KRAS_SIGNALING_UP [200] 2.15 e-4 1.79 e-3 
HALLMARK_ALLOGRAFT_REJECTION [200] 3.17 e-3 1.58 e-2 
HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSINSITION [20
0]* 
3.17 e-3 1.58 e-2 
HALLMARK_ESTROGEN_RESPONSE_EARLY [200] 3.17 e-3 1.58 e-2 
HALLMARK_INFLAMMATORY_RESPONSE [200] 3.17 e-3 1.58 e-2 
 
Table 1.4 GO analysis on Differential Mutated Genes between Pt_mRCC and PDX_mRCC 










HALLMARK_UV_RESPONSE_DN [144] 1.39 e-29 6.93 e-28 
HALLMARK_MYC_TARGETS_V1 [200] 2.75 e-27 6.87 e-26 
HALLMARK_MITOTIC_SPINDLE [200] 7.97 e-24 1.33 e-22 
HALLMARK_MTORC1_SIGNALING [200]* 9.49 e-20 1.19 e-18 
HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSINSITION [200]* 1.91 e-17 1.91 e-16 
HALLMARK_OXIDATIVE_PHOSPHORYLATION [200] 1.06 e-16 8.81 e-16 
HALLMARK_HYPOXIA [200]* 5.69 e-16 4.06 e-15 
HALLMARK_GLYCOLYSIS [200]* 2.97 e-15 1.86 e-14 
HALLMARK_ANDROGEN_RESPONSE [101] 1.07 e-14 5.96 e-14 





Table 1.5 Mean expression correlation between samples: Chung et al. 2017 
  BC03 BC09 BC03LN 
BC03   0.595 0.826 
BC09     0.648 
BC03LN       
 
Table 1.6 a Number of differential expressed gene between groups. b Number of differential 
expressed gene between groups overlapped with differential mutated genes 













BC03   178             
BC09 178               
BC03Mix1               110 
BC03Mix2               322 
BC03LN1               183 
BC09_1             34   
BC09_2           34     
Other within 
same tumor     110 322 183       
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BC03Mix1               71/110 
BC03Mix2               206/322 
BC03LN1               111/183 
BC09_1 
            
21/3
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BC09_2 
          
21/3
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Other within 










 SURFACE PROTEIN IMPUTATION FROM SINGLE CELL 
TRANSCRIPTOMES BY DEEP NEURAL NETWORK 
 Introduction 
Recent technological advances allow the simultaneous profiling, across many cells in parallel, of 
multiple omics features in the same cell [29, 87-90]. In particular, high throughput quantification of 
the transcriptome and a selected panel of cell surface proteins in the same cell is now feasible 
through the REAP-seq and CITE-seq protocols [88, 89].  Cell surface proteins can serve as 
integral markers of specific cellular functions and primary targets for therapeutic intervention. 
Immunophenotyping by cell surface proteins has been an indispensable tool in hematopoiesis, 
immunology and cancer research during the past 30 years. Yet, due to technological barriers and 
cost considerations, most single cell studies, including Human Cell Atlas project [91], quantify the 
transcriptome only and do not have cell-matched measurements of relevant surface proteins [22, 
92]. Sometimes, which cell types and corresponding surface proteins are essential become 
apparent only after exploration by scRNA-seq. This motivates our inquiry of whether protein 
abundances in individual cells can be accurately imputed by the cell’s transcriptome.  
We propose cTP-net (single cell Transcriptome to Protein prediction with deep neural 
network), a transfer learning approach based on deep neural networks that imputes surface 
protein abundances for scRNA-seq data. Through comprehensive benchmark evaluations and 
applications to Human Cell Atlas and acute myeloid leukemia data sets, we show that cTP-net 
outperform existing methods and can transfer information from training data to accurately impute 
24 immunophenotype markers, which achieve a more detailed characterization of cellular state 
and cellular phenotypes than transcriptome measurements alone. cTP-net relies, for model 





2.2.1 Method overview 
An overview of cTP-net is shown in Figure 2.1a. Studies based on both CITE-seq and REAP-seq 
have shown that the relative abundance of most surface proteins, at the level of individual cells, is 
only weakly correlated with the relative abundance of the RNA of its corresponding gene [88, 89, 
93]. This is due to technical factors such as RNA and protein measurement error [94], as well as 
inherent stochasticity in RNA processing, translation and protein transport [95-99]. To accurately 
impute surface protein abundance from scRNA-seq data, cTP-net employs two steps: (1) 
denoising of the scRNA-seq count matrix and (2) imputation based on the denoised data through 
a transcriptome-protein mapping (Figure 2.1a). The initial denoising, by SAVER-X [100], 
produces more accurate estimates of the RNA transcript relative abundances for each cell. 
Compared to the raw counts, the denoised relative expression values have significantly improved 
correlation with their corresponding protein measurement (Figure 2.1b, 2.2a, 2.3ab). Yet, for 
some surface proteins, such as CD45RA, this correlation for denoised expression is still 
extremely low.  
The production of a surface protein from its corresponding RNA transcript is a 
complicated process involving post-transcriptional modifications and transport [95], translation 
[96], post-translational modifications [97] and protein trafficking [98]. These processes depend on 
the state of the cell and the activities of other genes [93, 99]. To learn the mapping from a cell’s 
transcriptome to the relative abundance of a given set of surface proteins, cTP-net employs a 
multiple branch deep neural network (MB-DNN, Figure 2.4). Deep neural networks have recently 
shown success in modeling complex biological systems [101, 102], and more importantly, allow 
good generalization across data sets[100, 103]. Generalization performance is an important 
aspect of cTP-net, as we would like to perform imputation on tissues that do not exactly match 
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the training data in cell type composition. Details of the cTP-net model and training procedure, as 
well as of alternative models and procedures that we have tried, are in Methods. 
2.2.2 Imputation accuracy evaluation via random holdout 
To examine imputation accuracy, we first consider the ideal case where imputation is conducted 
on cells of types that exactly match those in training data. For benchmarking, we used peripheral 
blood mononuclear cells (PBMCs) and cord blood mononuclear cells (CBMCs) processed by 
CITE-seq and REAP-seq [88, 89], described in Table 2.1. We employed holdout method, where 
the cells in each data set were randomly partitioned into two sets: a training set with 90% of the 
cells and a holdout set with the remaining 10% of the cells for validation (Methods, Figure 2.5a). 
Each cell type is well represented in both the training and validation sets. Figure 2.1b and S3a 
show that, for all proteins examined in the CITE-seq PBMC data, cTP-net imputed abundances 
have much higher correlation to the measured protein levels, as compared with the denoised and 
raw RNA counts of the corresponding genes. We obtained similar results for the CITE-seq CBMC 
and REAP-seq PBMC data sets (Figure 2.3ab).  
2.2.3 Generalization accuracy to unseen cell types 
Next, we considered the generalization accuracy of cTP-net, testing whether it produces accurate 
imputations for cell types that are not present in the training set. For each of the high-level cell 
types in each data set in Table 2.2, all cells of the given type are held out during training, and 
cTP-net, trained on the rest of the cells, was then used to impute protein abundances for the held 
out cells (Methods, Figure 2.5b). We did this for each cell type and generated an “out-of-cell-type” 
prediction for every cell.  
Across all benchmarking data sets and all cell types, these out-of-cell-type predictions 
still improve significantly upon the corresponding RNA counts while slightly inferior in accuracy to 
the traditional holdout validation predictions above (Figure 2.6a, 2.3a). This indicates that cTP-net 
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provides informative predictions on cell types not present during training, vastly improving upon 
using the corresponding mRNA transcript abundance as proxy for the protein level.  
2.2.4 Generalization accuracy across tissue and lab protocol 
To further examine the case where cell types in the training and test data are not perfectly 
aligned, we considered a scenario where the model is applied to perform imputation on a tissue 
that differs from the training data. We trained cTP-net on PBMCs and then applied it to perform 
imputation on CBMCs, and vice versa, using the data from Stoeckius et al. [89] (Methods). Cord 
blood is expected to be enriched for stem cells and cells undergoing differentiation, whereas 
peripheral blood contains well-differentiated cell types, and thus the two populations are 
composed of different but related cell types. Figure 2.6a and 2.2b shows the result on training on 
CBMC and then imputing on PBMC. Imputing across tissue markedly improves the correlation to 
the measured protein level, as compared to the denoised RNA of the corresponding gene, but is 
worse than imputation produced by model trained on the same population. For practical use, we 
have trained a network using all cell populations combined, which indeed achieves better 
accuracy than a network trained on each separately (Methods, Figure 2.2b, 2.3ac). The weights 
for this network are publicly available at https://github.com/zhouzilu/cTPnet.  
We then tested whether cTP-net’s predictions are sensitive to the laboratory protocol, 
and in particular, whether networks trained using CITE-seq data yields good predictions by 
REAP-seq’s standard, and vice versa. Using a benchmarking design similar to above, we found 
that, in general, cTP-net maintains good generalization power across these two protocols (Figure 
2.6a, 2.2b).  
2.2.5 Imputation accuracy comparison to Seurat v3 
Seurat v3 anchor transfer [104] is a recent approach that uses cell alignment between data sets 
to impute features for single cell data. For comparison, we applied Seurat v3 anchor transfer to 
the holdout validation and out-of-cell-type benchmarking scenarios above (Methods). In the 
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validation scenario, we found the performance of cTP-net and Seurat v3 to be comparable, with 
cTP-net slightly better, as both methods can estimate protein abundance by utilizing marker 
genes to identify the cell types. cTP-net, however, vastly improves upon Seurat in the out-of-cell-
type scenario (Figure 2.6a, 2.7a). This is because cTP-net’s neural network, trained across a 
diversity of cell types, learns a direct transcriptome-protein mapping that can more flexibly 
generalize to unseen cell types, while Seurat v3 depends on a nearest neighbor method that can 
only sample from the training dataset. As shown by the cross-population and out-of-cell-type 
benchmarking above, cTP-net does not require direct congruence of cell types across training 
and test sets. 
In addition to predictions on unseen cell type, cTP-net also improves upon the existing 
state-of-the-art in capturing within cell-type variation in protein abundance. As expected, within 
cell-type variation is harder to predict, but cTP-net’s imputations nevertheless achieve high 
correlations with measured protein abundance for a subset of proteins and cell types (Figure 
2.2c, 2.3d). Compared to Seurat v3, cTP-net’s imputations align more accurately with measured 
protein levels when zoomed into cells of the same type (Figure 2.6b, 2.7b); see Figure 2.6c, for 
example, CD11c in CD14-CD16+ monocytes, CD2 in CD8 T cells, and CD16 in dendritic cells. All 
of these surface proteins have important biological function in the corresponding cell types, as 
CD11c helps trigger respiratory burst in monocyte [105], CD2 co-stimulates molecule on T cells 
[106] and CD16 differentiate DC subpopulation [107]. The learning of such within-type 
heterogeneity gives cTP-net the potential to attain higher resolution in the discovery and labeling 
of cell states. 
2.2.6 Network interpretation and feature importance 
What types of features are being used by cTP-net to form its imputation? To interpret the 
network, we conducted a permutation-based interpolation analysis, which calculates a 
permutation feature importance for each protein-gene pair (Methods, Figure 2.8a). Interpolation 
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can be done using all cells, or cells of a specific type, the latter allowing us to probe relationships 
that may be specific to a given cell type. Applying this analysis to cTP-net trained on PBMC, we 
found that, at the level of the general population that includes all cell types, the most important 
genes for the prediction of each protein are those that exhibit the highest cell-type specificity in 
expression (Table 2.3).  This is because most of these surface proteins are cell type markers, and 
thus when cells of all types are pooled together, “cell type” is the key latent variable that underlies 
their heterogeneity. In addition, as cell-type markers are usually redundant and predictable by 
other genes, the model still performs well after removing corresponding surface protein genes 
during training (Table 2.4, 2.5). Within cell type interpolation, on the other hand, reveals genes 
related to RNA processing, RNA binding, protein localization and biosynthetic processes, in 
addition to immune-related genes that differentiate the immune cell sub-types (Table 2.6). This 
analysis shows that cTP-net combines different types of features, both cell type markers and 
genes involved in RNA to protein conversion and transport, to achieve multiscale imputation 
accuracy. 
In addition, we analyzed the bottleneck layer with 128 nodes before the network 
branched out to the protein-specific layers. We performed dimension reduction (UMAP) directly 
on the bottleneck layer intermediate output of 7000 PBMCs from CITE-seq. Figure 2.8b shows 
that the cells are cleanly separated into different clusters, representing cell types as well as 
gradients in surface protein abundance. This confirms that the bottleneck layer captures the 
essential information on cell stages and transitions, and that each subsequent individual branch 
then predicts its corresponding protein’s abundance. 
2.2.7 Application to Human Cell Atlas 
Having benchmarked cTP-net’s generalization accuracy across immune cell types, tissues, and 
technologies, we then applied the network trained on the combined CITE-seq dataset of 
PBMCs,CBMCs and bone marrow mononuclear cells (BMMCs) [89, 104] to perform imputation 
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for the Human Cell Atlas CBMC and BMMC data sets (Table 2.1). Figure 2.9 shows the raw RNA 
count and predicted surface protein abundance for 24 markers across 6023 BMMCs from sample 
MantonBM1 and 4176 CBMCs from sample MantonCB1. (Similar plots for the other 7 BMMC and 
7 CBMC samples are shown in Figure 2.10, 2.11). Similar to what was observed for actual 
measured protein abundances in the CITE-seq and REAP-seq studies, the imputed protein levels 
differ markedly from the RNA expression of its corresponding gene, displaying higher contrast 
across cell types and higher uniformity within cell type. Thus, the imputed protein levels serve as 
interpretable intermediate features for the identification and labelling of cell states, defining cell 
subtypes more clearly than the RNA levels of the corresponding marker genes. For example, 
imputed CD4 and CD8 levels separate CD4+ T cells from CD8+ T cells with high confidence. 
Further separation of naïve T cells to memory T cells can be achieved through imputed 
CD45RA/CD45RO abundance, as CD45RA is a naïve antigen and CD45RO is a memory 
antigen. Consistent with flow cytometry data, the large majority of CB T cells are naïve, whereas 
the BM T cell population is more diverse [108]. Also, for BM B cells that have high imputed CD19 
levels, cTP-net allows us to confidently distinguish the Pre.B (CD38+, CD127+), immature B 
(CD38+, CD79b+), memory B (CD27+) and naïve B cells (CD27-), whose immunophenotypes 
have been well characterized [109].  
In addition, consider natural killer cells, in which the proteins CD56 and CD16 serve as 
indicators for immunostimulatory effector functions, including an efficient cytotoxic capacity [110, 
111]. We observe an opposing gradient of imputed CD56 and CD16 levels within 
transcriptomically derived natural killer (NK) cell clusters that reveal CD56bright and CD56dim 
subsets, coherent with previous studies[89] (Figure 2.6f, 2.12, F-test: p-value = 1.667e-15). This 
pattern is not found in RNA abundances due to low expression (F-test: p-value= 0.9377). 
Between CD56brignt and CD56dim subsets, 7 out of 10 of previously studied differentially expressed 
genes are significant in the single cell analysis (Fisher test: p-value = 1.07e-04) [89, 112, 113]. 
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This gradient in CD56 and CD16, where decrease in CD56 is accompanied by increase in CD16, 
is replicated across the 8 CBMC and 8 BMMC samples in HCA (Figure 2.10, 2.11, 2.12). 
Consider also the case of CD57, which is a marker for terminally differentiated 
“senescent” cells in the T and NK cell types. The imputed level of CD57 is lower in CBMCs 
(fetus’s blood), and rises in BMMCs (95% quantile: bootstrap p-value<1e-6). This is consistent 
with expectation since CD57+ NK cell and T cell populations grow after birth and with ageing 
[114-116] (Figure 2.10, 2.11).   
These results demonstrate how cTP-net, trained on a combination of PBMCs, CBMCs 
and BMMCs, can impute cell type, cell stage, and tissue-specific protein signatures in new data 
without explicitly being given the tissue of origin. 
2.2.8 Application to Acute Myeloid Leukemia 
We further apply cTP-net to an acute myeloid leukemia (AML) data set from Galen et al. [31]. 
AML is a heterogeneous disease where the diversity of malignant cell types partially recapitulates 
the stages of myeloid development. Mapping the malignant cells in AML to the differentiation 
stage of their cell of origin strongly impacts tumor prognosis and treatment, as malignant cells 
that originate from earlier stage progenitors have higher risk of relapse [117, 118]. In the original 
paper, the authors sequenced 7698 cells from 5 healthy donors to build a reference map of cell 
types during myeloid development, and then mapped 30712 cells from 16 AML patients across 
multiple time points to this reference to identify the differentiation stage of the malignant cells. 
Here, by imputing 24 immunophenotype markers with cTP-net, we can directly characterize the 
differentiation stage of cell-of-origin for the malignant cells.  
Figure 2.13a is a UMAP plot based on imputed surface protein abundance of 5 normal 
BMs and 12 Day 0 samples from AML patients. The majority of the malignant cells as identified in 
the original paper reside on the right half of the plot, which recapitulate the myeloid differentiation 
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trajectory as revealed by the imputed values of canonical protein markers (Figure 2.13b): From 
CD34+ progenitors to CD38+CD123+ cells in transition to CD11c+ and CD14+ mature 
monocytes [119].  All of the malignant cells have imputed protein values that place them along 
this monocyte lineage. Using the transcriptome for visualization, on the other hand, reveals large 
batch effects across samples, due to both technical batch and biological differences (Figure 
2.14).  Thus, unlike the imputed protein data, the transcriptomic data cannot be directly combined 
without alignment.    
Based on the trajectory revealed by the imputed protein levels, we can determine the 
differentiation cell stage(s) for the malignant cells of each tumor, according to which the 12 AML 
patients can be divided into three categories: (1) AMLs of single differentiation stage (AML420B, 
AML556, AML707B and AML916; Figure 2.13c), (2) AMLs of two differentiation stages 
(AML210A, AML328, AML419A and AML475; Figure 2.13e) and (3) AMLs of many differentiation 
stages (AML1012, AML329, AML870 and AML921A; Figure 2.13f). This stage assignment is 
consistent with the original study [31]. For example, AML419A harbors two malignant cell types at 
opposite ends of the monocyte differentiation axis, distinguished by imputed CD34 and CD11c 
levels as CD34+CD11c- indicates progenitor-like and CD34-CD11c+ indicates differentiated 
monocyte-like cells (Figure 2.13d, 4e). AML707B, which carries a RUNX1/RUNX1T1 fusion, 
consists of cells of a specific cell stage that is distinct from the normal myeloid trajectory (Figure 
2.13c). Such unique cell cluster was due to hyper CD38 level in surface protein prediction (Figure 
2.13d). Such hyper-CD38 levels have been reported in AMLs with RUNX1/RUNX1T1 fusion[120-
122] and recent studies have also shown that CD38 can be a potential target for adult AML[123, 
124].   
In this example, the imputed protein levels served as useful features for trajectory 
visualization.  This analysis also indicates that even though cTP-net is currently trained only on 
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normal immune cells, it can reveal disease-specific signatures in malignant cells and the imputed 
protein levels are useful for characterizing tumor phenotypes. 
 Discussion 
Taken together, our results demonstrate that cTP-net can leverage existing CITE-seq and REAP-
seq datasets to predict surface protein relative abundances for new scRNA-seq data sets, and 
that the predictions generalize to cell types that are absent from, but related to those in the 
training data. cTP-net was benchmarked on PBMC and CBMC immune cells, showing good 
generalization across tissues and technical protocols.  On Human Atlas Data, we show that the 
imputed surface protein levels allow easy assignment of cells to known cell types, as well as the 
revealing of intra-cell type gradients. We then demonstrate that, even though cTP-net used only 
immune cells from healthy individuals for training, it is able to impute immunophenotypes for 
malignant cells from acute myeloid leukemia, and that these immunophenotypes allow placement 
of the cells along the myeloid differentiation trajectory.  Furthermore, we show that cTP-net is 
able to impute protein signatures in the malignant cells that are disease specific and that are not 
easily detectable from the transcriptomic counts.     
SAVER-X serves an important role in the training procedure of cTP-net. As shown in 
Table 2.4, without SAVER-X denoising, the cTP-net prediction performance retracts by 0.02 in 
correlation, more significant than any other parameter tweaks. This discrepancy in performance is 
due to: (1) SAVER-X makes use of the noise model to obtain estimates of the true RNA counts. 
This helps cTP-net learn the underlining relationship between true RNA counts and protein level, 
rather than the noisy raw counts and protein levels, which varies more across data sets and thus 
does not generalize well. (2) By denoising the scRNA-seq, the input for learning the RNA-protein 
relationship is less sparse. Manifold learning on a more continuous input space usually works 
better[125, 126]. (3) Comparing to other autoencoder based denoising method, SAVER-X 
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performs Bayesian shrinkage on top of autoencoder framework to prevent over-imputation (over-
smoothing) [100, 127]. 
Despite these promising results, cTP-net has limitations. (1) cTP-net can only apply to 
count based expression input (UMI-based). CITE-seq data with TPM and RPKM expression 
metric is not available for testing. Thus, the prediction accuracy is unknown. (2) The 
generalization ability of cTP-net to unrelated cell types has limitations. Even though the final cTP-
net model, trained on immune cells, has good results on immune cells from diverse settings, we 
have not tried to perform imputation of these immune-related markers on cells that are not of the 
hematopoietic lineage. 
With the accumulation of publicly available CITE-seq and REAP-seq data across diverse 
proteins, cell types and conditions, cTP-net can be retrained to accommodate more protein 
targets and improve in generalization accuracy. The possibility of such cross-omic transfer 
learning underscores the need for more diverse multi-omic cell atlases, and demonstrate how 
such resources can be used to enhance future studies. The cTP-net package is available both in 
Python and R at https://github.com/zhouzilu/cTPnet.  
 Methods 
2.4.1 Data sets and pre-processing 
Table 2.1 summarizes the five data sets analyzed in this study: CITE-PBMC, CITE-CBMC, 
REAP-PBMC, HCA-CBMC and HCA-BMMC. Among these, CITE-PBMC, CITE-CBMC and 
REAP-PBMC have paired scRNA-seq and surface protein counts, while HCA-CBMC and HCA-
BMMC have only scRNA-seq counts. For all scRNA-seq data sets, low quality gene (< 10 counts 
across cells) and low-quality cells (less than 200 genes detected) are removed, and the count 
matrix (𝐶) for all remaining cells and genes is used as input for denoising. scRNA data denoising 
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was performed with SAVER-X using default parameters. Denoised counts (Λ) were further 
transformed with Seurat default LogNormalize function, 




where Λ𝑖𝑗 is the denoised molecule count of gene 𝑖 in cell 𝑗, and 𝑚𝑗 is the sum of all molecule 
counts of cell 𝑗. The normalized denoised count matrix 𝑋 is the training input for the subsequent 
multiple branch neural network. For the surface protein counts, we adopted the relative 
abundance transformation from Stoeckius et al.[89]. For each cell 𝑐, 
𝑦𝑐 = [ln (
𝑝1𝑐
𝑔(𝐩𝑐)
) , ln (
𝑝2𝑐
𝑔(𝐩𝑐)
) … ln (
𝑝𝑑𝑐
𝑔(𝐩𝑐)
)]  (2) 
where 𝐩𝑐 is vector of antibody-derived tags (ADT) counts, and 𝑔(𝐩𝑐) is the geometric mean of 𝐩𝑐. 
The network trained using this transformed relative protein abundance as the response vector 
yields better prediction accuracy than the network trained using raw protein barcode counts. 
2.4.2 cTP-net neural network structure and training parameters 
Figure 2.4 shows the structure of cTP-net. Here, we have a normalized expression matrix 𝐗 of 𝑁 
cells and 𝐷 genes, and a normalized protein abundance matrix 𝐘 of the same 𝑁 cells and 𝑑 
surface proteins. Let’s denote cTP-net as a function 𝐹 that maps from ℝ𝐷 to ℝ𝑑. Starting from the 
input layer, with dimension equals to number of genes 𝐷, the first internal layer has dimension 
1000, followed by a second internal layer with dimension 128. These two layers are designed to 
learn and encode features that are shared across proteins, such as features that are informative 
for cell type, cell state and common processes such as cell cycle. The remaining layers are 
protein specific, with 64 nodes for each protein that feed into a one node output layer giving the 
imputed value. All layers except the last layer are fully connected (FC) with rectified linear unit 
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(ReLU) activation function [128], while the last layer is a fully connected layer with identity 
activation function for output. The objective function here is, 
argmin
𝐹
|𝐘 − 𝐹(𝐗)|1   (3) 
where the loss is L1 norm. The objective function was optimized stochastically with Adam [129] 
with learning rate set to 10e-5 for 139 epochs (cross-validation). Other variations of cTP-net, 
which we found to have inferior performance, are illustrated in more details in Table 2.4. The first 
column indicates the differences to the finalized models, while the second column shows the 
correlation of the predicted protein abundance to the true protein abundance in the holdout 
setting on CITE-seq CBMC data set. As shown by Table 2.4, missing any component of the final 
model will result in inferior performance.  
2.4.3 Benchmarking procedure 
Figure 2.5a shows the validation set testing procedure. Given limited amount of data, we keep 
only 10% of the cells as the testing set, and use the other 90% of the cells for training. The 
optimal model was selected based on the testing error.  
We perform the out-of-cell type prediction based on Figure 2.5b. This procedure mimics 
cross-validation, except that, instead of selecting the test set cells randomly, we partition the cells 
by their cell types. Iteratively, we designate all cells of a given cell type for testing and use the 
remaining cells for training. We then perform prediction on the hold-out cell type using the model 
trained on all other cell types. In the end, every cell has been tested once and has the 
corresponding predictions. In the benchmark against the validation set testing procedure, we limit 
comparisons to the same cells that were in the validation set in the holdout scheme to account for 
variations between subsets. 
To apply the models we trained in validation set testing procedure to different cell 
populations and technologies, the inputs have to be in the same feature space. Even though all 
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data sets considered are from human cells, the list of genes differs between experiments and 
technologies. Genes that are in the training data but not in the testing data are filled with zeros. 
Because cTP-net utilizes overrepresented number of genes to predict the surface proteins level, 
having a small number of genes missing has little effect on the performance. After prediction, we 
selected only the shared proteins between two data sets for comparison. 
2.4.4 cTP-net interpolation 
To better interpret the relationships that the neural network is learning, we developed a 
permutation-based interpolation scheme that can calculate an influence score 𝑒𝑝𝑖 for each gene 
in the imputation of each protein (Figure 2.8). The idea is to assess how much changing the 
expression value of certain genes in the training data affects the training errors for a given 
model 𝐹. In each epoch, we interpolate all of the genes in a stochastic manner. Let’s denote 𝐗 as 
the expression matrix (𝑁 by 𝐺 matrix, where 𝑁 is the number of cells and 𝐺 is number of genes), 
𝐘 as protein abundance matrix and 𝐿 as the loss function. The algorithm goes as follow (Figure 
2.8): 
(1) Estimate the original model error 𝜖𝑜𝑟𝑖𝑔 = 𝐿(𝐘, 𝐹(𝐗)). 
(2) Sampling batch of genes denote by  . Generate expression matrix 𝐗𝑝𝑒𝑟𝑚 by permuting 
genes in 𝑔𝑠 in the data 𝐗. This breaks the association between 𝑔𝑠 and protein 
abundance 𝐘, i.e. the cell order within 𝑔𝑠 does not coordinate with protein abundance 𝐘.  
(3) Estimate error 𝜖𝑝𝑒𝑟𝑚 = 𝐿(𝐘, 𝐹(𝐗𝑝𝑒𝑟𝑚)) based on the predictions of the permuted data. 
(4) Calculate permutation feature importance Δ𝑔𝑠 = |𝜖
𝑜𝑟𝑖𝑔 − 𝜖𝑝𝑒𝑟𝑚| of gene set 𝑔𝑠 to this 
model 𝐹. 
We set batch size as 100 with 500 epochs. Furthermore, by picking different cells to 
interpolate, we could identify gene influence score in different cell types. For example, if matrix 𝐗 
belongs to a given cell type, the cell type specific genes are consistent across cells of the given 
cell type, and thus, the permutation will not influence these genes. Genes that influence the 
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surface protein abundance within the cell type, such as cell cycle genes and protein synthesis 
genes, tend to be rewarded with high influence scores in such a cell-type specific interpolation 
analysis.  
For the top 100 highest influence scored genes from the following scenarios in CITE-PBMC: 
(1) CD45RA in CD14-CD16+ monocytes, (2) CD11c in CD14-CD16+ monocytes, (3) CD45RA in 
CD8 T cells, (4) CD45RA in CD4 T cells, (5) CD11c in CD14+CD16+ monocytes, (6) CD45RA in 
dendritic cells, and (7) CD11c in dendritic cells, we employed a Gene Ontology analysis [57] 
which identify top 10 pathways based on GO gene sets with FDR q-value < 0.05 as significant 
(Table 2.6). 
2.4.5 Seurat anchor-transfer analysis 
We compared cTP-net with an anchor-based transfer learning method developed in Seurat v3 
[104]. For Seurat v3, RNA count data are normalized by LogNormalization method, while surface 
protein counts are normalized by centered log-ratio (CLR) method. In validation test setting, we 
used the same cells for training and testing as in cTP-net so as to be directly comparable to cTP-
net. For out-of-cell type prediction, default parameters did not work for several cell types in 
anchor-transfer step, because, for those cell types, there are few anchors shared between the 
training and testing sets. To overcome this, we reduced the number of anchors iteratively until the 
function ran successfully. 
2.4.6 HCA data analysis 
HCA RNA-seq data sets are pre-processed as discussed above, resulting in log-normalized 
denoised values. We applied default pipeline of Seurat and generated UMAP plot for both data 
sets (Figure 2.15). Cells are clearly clustered by individuals, indicating strong batch effects. As a 
result, the following analysis was performed on cells of each individual. Major cell types were 
determined by known markers. 
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From the log-normalized denoised expression value, we predict the surface protein 
abundance with cTP-net model trained jointly on CITE-seq PBMC, CBMC and BMMC data sets. 
We embedded 24 surface protein abundance across 16 individuals on t-SNE plot, showing 
consistent results with cell type information (Figure 2.10, 2.11).  
 Data availability 
Public datasets for training and evaluating cTP-net can be found at National Center for 
Biotechnology Information Gene Expression Omnibus (GEO) under accession number 
GSE100866, GSE100501 and GSE128639 respectively. 
 Code availability 
cTP-net package are publicly available as both an open-source R package at 
https://github.com/zhouzilu/cTPnet with license GPL-3.0 and an open-source python package at 













Figure 2.1 cTP-net analysis pipeline and imputation of example proteins. (a) Overview of 
cTP-net analysis pipeline, which learns a mapping from the denoised scRNA-seq data to the 
relative abundance of surface proteins, capturing multi-gene features that reflect the cellular 
environment and related processes. (b) For three example proteins (CD3, CD4 and CD8), cross-
cell scatter and correlation (cor) of CITE-seq measured abundances vs. (1) raw RNA count 
(“CD3s” and “CD8s” are sum of all genes that compose protein CD3 and CD8, see Table 2.5), (2) 











Figure 2.2 Benchmark evaluation of cTP-net on CITE-PBMC data set. (a) Benchmark 
correlation of true protein level vs. (1) Raw RNA count, (2) SAVER-X denoised RNA level, and (3) 
cTP-net predicted protein abundance in holdout method. (b) Benchmark correlation of truth 
protein level vs. (1) transfer learning from CITE-CBMC, (2) transfer learning from CITE-
PBMCCBMC, and (3) transfer learning from REAP-PBMC. (c) Benchmark correlation of true 











Figure 2.3 Benchmark evaluation of cTP-net on CITE-CBMC data set. (a) Benchmark 
evaluation heatmap of cTP-net and comparison with Seurat v3. The table on the left captures the 
detailed training scheme and model name of each test. (b) Benchmark correlation of true protein 
level vs. (1) Raw RNA count, (2) SAVER-X denoised RNA level, and (3) cTP-net predicted 
protein abundance in holdout method. (c) Benchmark correlation of truth protein level vs. (1) 
transfer learning from CITE-PBMC, and (2) transfer learning from CITE-PBMCCBMC. (d) Benchmark 
correlation of true protein level vs. cTP-net prediction in holdout method for each cell type. 
 


















Figure 2.6 Benchmark evaluation on CITE-seq PBMC data. (a) Benchmark evaluation of cTP-
net on CITE-seq PBMC data, with comparisons to Seurat v3, in validation, across cell type, 
across tissue and across technology scenarios. The table on the left shows the training scheme 
of each test, the heatmap shows correlations with actual measured protein abundances. (b) 
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Within cell type correlations between imputed and measured protein abundance on the CITE-seq 
PBMC data, Seurat v3 versus cTP-net. Each point (color and shape pair) indicates a cell type and 
surface protein pair, where the x-axis is correlation between actual measured abundance and 
Seurat imputation and y-axis is the correlation between actual measured abundance and cTP-net 
imputation. (c) Scatter of imputed versus measured abundance for the three (surface protein, cell 
type) pairs marked by arrows in (b): CD11c in CD14-CD16+ monocytes, CD2 in CD8 T cells, and 








Figure 2.7 Benchmark evaluation of Seurat v3 on CITE-PBMC data set. (a) Benchmark 
correlation of true protein level vs. (1) cTP-net predicted protein abundance in holdout method, 
(2) Seurat v3 predicted protein abundance in holdout method, (3) out-of-cell-type cTP-net 
predicted protein abundance, and (4) out-of-cell-type Seurat v3 predicted protein abundance. (b) 
Benchmark correlation of truth protein level vs. (1) transfer learning from CITE-PBMC, and (2) 
transfer learning from CITE-PBMCCBMC. (c) Benchmark correlation of true protein level vs. cTP-





Figure 2.8 Interpolation analysis. (a) Interpolation procedure in identify permutation based 
importance score for each gene in each protein prediction. (b) Dimension reduction analysis on 




Figure 2.9 Imputation results analysis on Human Cell Atlas data sets. (a) Left panel: UMAP 
visualization of MantonBM1 BMMCs T cell subpopulation based on RNA expression, colored by 
cell type. CD4 T: mature CD4+ T cells; mature CD8 T: CD8+ T cells; naïve CD4 T: naïve CD4+ T 
cells; naïve CD8 T: naïve CD8+ T cells; CD8 senescent T: CD8+ senescent T cells. Right panel: 
Related imputed protein abundance and RNA expression of its corresponding gene. (b) UMAP 
visualization of MantonBM1 BMMCs based on RNA expression, colored by cell type. B: B cells; 
CD4 T: CD4+ T cells; CD8 T: CD8+ T cells; cMono: classical monocyte; ncMono: non-classical 
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monocyte; NK: natural killer cells; Pre.: precursors; Plasma: plasma cells. (c) Left panel: UMAP 
visualization of MantonBM1 BMMCs B cell subpopulation based on RNA expression, colored by 
cell type. Pre.B: B cell precursors; immature B: immature B cells; memory B: memory B cells; 
naïve B: naïve B cells. Right panel: Related imputed protein abundance and RNA expression of 
its corresponding gene. (d) UMAP visualization of MantonCB2 CBMCs based on RNA 
expression, colored by cell type. (e) cTP-net imputed protein abundance and RNA read count of 
its corresponding gene for 24 surface proteins. (f) UMAP visualization of MantonCB2 CBMCs NK 
cell subpopulation colored by CD56 and CD16 imputed protein abundance and RNA read count. 
Reverse gradient is observed in cTP-net prediction but not in the read count for its corresponding 
RNA. (g) Contour plot of cells based on imputed CD56 and CD16 abundance in NK cell 

















Figure 2.10 cTP-net prediction on Human Cell Atlas CBMCs by individual. For each 
individual, we show (1) t-SNE visualization of HCA CBMCs based on expression. B: B cells; CD4 
T: CD4 T cells; CD8 T: CD8 T cells; cMono: classic Monocyte; NK: Natural killer cells; Pre.: 
Precursors. (2) cTP-net imputed protein abundance and RNA of its cognate gene across 24 















Figure 2.11 cTP-net prediction on Human Cell Atlas BMMCs by individual. For each 
individual, we show (1) t-SNE visualization of HCA BMMCs based on expression. B: B cells; CD4 
T: CD4 T cells; CD8 T: CD8 T cells; Mono: Monocyte; NK: Natural killer cells; Pre.: Precursors. 
(2) cTP-net imputed protein abundance and RNA of its cognate gene across 12 different surface 
proteins. 
 
Figure 2.12 Contour plot of cells based on imputed CD56 and CD16 abundance in NK cell 
populations. (a) NK cells across all samples from HCA CBMC. (b) NK cells across all samples 




Figure 2.13 Imputation results analysis on Acute Myeloid Leukemia data sets. (a) UMAP 
visualization of normal cells and malignant cells from 12 AML samples at Day0 based on imputed 
protein abundance (red: malignant cells; grey: normal cells). (b) UMAP visualization of the 
myeloid trajectory. cTP-net imputed protein abundance of markers that perfectly recapitulate the 
myeloid development. (c, e, f) UMAP visualization of the myeloid trajectory with corresponding 
malignant cells from AML sample highlighted. (d) Plot of normal cells (grey contour) and AML 




Figure 2.14 UMAP plots of AML data set, colored by samples. (a) Dimension reduction on 




Figure 2.15 Human Cell Atlas t-SNE plot based on normalized expression. (a) t-SNE plot on 
Human Cell Atlas CBMCs based on normalized expression. Color indicates sample IDs. (b) t-
SNE plot on Human Cell Atlas BMMCs based on normalized expression. Color indicates sample 
IDs. Strong batch effects observed in both data sets. 
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# of cell 
types 
CITE-PBMC CITE-seq PBMC 1 7667 13517 10 8 
CITE-CBMC CITE-seq CBMC 1 8005 14505 10 12 
REAP-PBMC REAP-seq PBMC 1 4326 10811 10 NA 
CITE-BMMC CITE-seq BMMC 1 33455 17009 25 NA 
HCA-CBMC 10x CBMC 8 260,000 12611 NA NA 
HCA-BMMC 10x BMMC 8 270,000 12611 NA NA 
 
Table 2.2 Cell type summary of CITE-seq data sets 
Data Cell types 
CITE-PBMC B, CD8 T-1, CD4 T, NK, DC, CD14+CD16+ Mono, 
CD14-CD16+ Mono, CD8 T 2 
CITE-CBMC B, CD8 T, CD4 T, NK, DC, CD14+ Mono, CD16+ 







Table 2.3 Top 20 highest influence score genes for each protein in CITE-PBMC data set 
CD3 CD4 CD8 CD2 CD45RA CD57 CD16 CD14 CD11c CD19 
CD3D CD8B CD8B CCL5 KLRB1 NUDT6 CHL1 C1orf115 CFD CCL5 
IL7R CD8A CD8A IL7R CCL5 MZT2A 
RP11-
242C19.2 







EIF1AX ATP2A2 GCSH ALDH7A1 ANKRD36C 
RN7SL600
P 






TST PKNOX1 DBF4 ISYNA1 IGLL5 HSF2 





HELLS DDIT3 ZAP70 LINC00384 ZFAS1 
CTA-
217C2.1 




BMP8B ACAP2 TAPSAR1 CNOT11 TIMM21 SLC4A7 SLC6A16 GLB1L 
FGD5-AS1 C18orf25 FAH PPCDC PLEKHF1 HSD17B4 MRPS18C MIER3 LRRC16A LIMD2 
COMMD7 FPGT AC009299.3 ANKRD39 
CTBP1-
AS2 
CLEC4E C7orf43 SLC11A2 TRAF1 DTX3L 
CTA-
292E10.8 
NETO2 CMKLR1 AIM2 CYP27A1 FAM98C GORASP2 ZAP70 PABPN1 PTCD2 
ZC2HC1A GDAP1 ENTPD1 TTLL12 MAN1A2 PRMT1 
CTD-
2555C10.3 
MAP4 ADM LPAR1 


















ZBTB38 FAM63A USP32 
PACSIN1 SLC4A10 7-Sep U91328.20 FCGR3A VPS26A FKBP7 PIK3R1 RPL34 AIM2 
ARID4B FAAH2 CDT1 EIF4H 
CCDC163
P 
ECHS1 RNF24 PIGG FAM118B SLC12A7 
ATP11A AP5B1 QRICH1 AC073115.7 POLR1C 
FLVCR1-
AS1 
TBXAS1 DESI2 UBQLN4 ZNF671 
RN7SL521
P 
DHPS AP2M1 RP11-4O1.2 PRSS35 
RP11-
421L21.2 




Table 2.4 Summary table of different cTP-net models 
Differences to the finalized model Correlation 
Without SAVER-X denoising, without MB structure 0.961±0.0004 
Without MB structure 0.968±0.0005 
Without SAVER-X denoising  0.959 ±0.0005 
L2 loss 0.969±0.0002 
Set bottle neck layer to 256 nodes (128 in final model) 0.968±0.0003 
Set bottle neck layer to 64 nodes (128 in final model) 0.968±0.0003 
With additional shared layers 0.969±0.0004 
With SeLU activation function 0.966±0.0002 
With Dropout layer between layer1 and layer2 0.966±0.001 
Exclude genes corresponding to targeted proteins 0.967±0.0001 







Table 2.5 List of surface proteins and corresponding genes 




























Table 2.6 Gene set enrichment analysis on cell-immunophenotype pairs that cTP-net predict well 
in CITE-PBMC data set 
Surface 
protein 







































































































 INTEGRATIVE DNA COPY NUMBER DETECTION AND GENOTYPING 
FROM SEQUENCING AND ARRAY-BASED PLATFORMS WITH PENN MEDICINE 
BIOBANK 
 Introduction 
Copy number variations (CNV) are large chunks of DNA that have been deleted or duplicated 
during evolution, leading to polymorphisms in their numbers of copies in the observed population. 
Studies have shown that CNV is an important type of variation in the human genome, some of 
which playing key roles in disease susceptibility [130-132]. Accurate identification and genotyping 
of CNV is important for population genetic and disease studies, and can lead to improved 
understanding of disease mechanisms and discovery of drug targets [133-135]. To profile CNV, 
earlier studies relied on array-based technologies such as array comparative genome 
hybridization (CGH) or single-nucleotide polymorphism (SNP) genotyping arrays, while in recent 
years, next generation sequencing (NGS) technologies have allowed for high resolution CNV 
profiling [136-143]. With the drop in sequencing cost, many large cohort profile both array data 
and NGS data from same sample. Such design allows better sensitivity and specificity of CNV 
detection. We recently developed a statistical framework, integrated Copy Number Variation 
caller (iCNV), that can be applied to study design of combination of SNP and sequencing data 
[144]. Compared to existing approaches, iCNV improves copy number detection accuracy in 
three ways: (1) utilization of B allele frequency information from sequencing data, (2) integration 
of sample matched SNP-array data, and (3) integration of improved platform-specific 
normalization for sequencing coverage. iCNV produces a cross-platform joint segmentation of 
each sample’s genome into deleted, duplicated, and normal regions, and further infers integer 
copy numbers in deletion and duplication regions.  
Recent years’ developments of large genomic biobank propose great opportunity for CNV 
studies across many phenotypes[145, 146]. The Penn Medicine BioBank (PMBB), a diverse 
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cohort, currently consists of paired SNP array and whole exome sequencing (WES) data from 
2219 African ancestry samples and 8078 European ancestry samples. A complete profile of 
CNVs of all PMBB samples in companion with detailed patient health information can provide a 
great resources for researchers to understand the relationship between germline CNVs and 
various phenotype. In order to adjust to large number of samples, we improve iCNV with an 
efficient Map-Reduce algorithm for CNV detection that reduce computation time and boost 
robustness [147].  
  Methods 
3.2.1 Penn Medicine BioBank 
PMBB recruits participants by enrolling at the time of appointment through the University of 
Pennsylvania Health System. Patients are asked to donate either blood or a tissue sample and 
allow researchers access to their electronic health record (EHR). This provides researchers with 
access to a large resources of genomic data with attached health information. PMBB currently 
consists of 8078 European ancestry samples and 2219 African ancestry samples with paired 
SNP array and WES data. 
3.2.2 Pipeline overview 
Fig. 3.1 shows an overview of iCNV analysis pipeline. Input data depends on experiment design: 
When both SNP array and NGS data are available, the input includes (i) SNP log R ratio (LRR) 
and (ii) B allele frequency (BAF), which quantify, respectively, relative probe intensity and allele 
proportion, and (iii) sequencing mapped reads (BAM file) [146, 148]. For sequencing data, iCNV 
also receives target positions (BED file) for read depth background normalization. In WES, the 
targets are exons, while for WGS, iCNV automatically bins the genome and treats each bin as a 
target (the default bin size is 1kb). iCNV first performs cross-sample bias correction for 
sequencing data using CODEX and computes a Poisson log-likelihood ratio (PLR) for each target 
[137]. As suggested, samples with different ethnicity needed to be separated for analysis. In 
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addition, the sequencing batch information of the samples is unavailable. In order to have an 
unbiased normalization method, we performed permutation-based test which will introduce in the 
next section (Fig. 3.2). Heterozygous SNPs are detected and BAFs are computed within target 
regions using SAMTOOLS [148]. Integrated CNV detection is then conducted through a hidden 
Markov model (HMM) that treats the array intensity, array BAF, sequencing PLR and sequencing 
BAF as observed emissions from a hidden copy number state. The HMM segments the genome 
of each sample into regions of homogeneous copy number and outputs an integrated Z-score for 
each position that summarizes the evidence for an abnormal copy number at that position. 
Integer-valued copy numbers are then estimated in regions of high absolute Z-score, utilizing 
information from all platforms.  Finally, we filters out small CNVs with size less than 10kb as well 
as untrustful regions, such as immunoglobulin regions. 
3.2.3 Map-Reduce framework for efficient and robust CNV detection 
Due to large number of samples and missing batch information, we design a map-reduce 
framework aiming to reduce computational time and improve CNV detection robustness. Analysis 
shows that the step of calculating Poisson log likelihood ratio is the bottleneck steps. This is due 
to large samples size, intractable RAM, multi-core inability as well as unavailable of batch 
information. As a result, we randomly partition the samples into batches of size around 100 and 
remove the biases at batch level illustrated in Fig 3.2. In this computational step, we map the data 
set into a number of workers in the computer cluster, where the normalization was performed per 
worker (i.e. the map step). We further combine the normalized data in individual batch into a full 
dataset and apply HMM algorithm for CNV detection (i.e. the reduce step). Owning to the fact that 
we do not have batch information, we permute the batch assignment 5 times and take a majority 
vote of the CNV calls to ensure detection robustness. Such framework reduces the computational 




3.3.1 CNV summary of samples  
Fig. 3.3 provides an example of heatmap of the CNV scores across 120 samples, with blue 
illustrates higher chance of duplication and red illustrates higher chance of deletion. Dark blue 
dots and dark red dots indicates CNV calls of duplication and deletion respectively. The CNV 
distribution of European ancestry (EUR) samples is illustrated in Fig. 3.4a. iCNV detects on 
average 34.1 deletions and 11.3 duplications per EUR sample. Fig. 3.4c shows the CNV 
distribution of African ancestry (AFR) samples. iCNV detects on average 38 deletions and 10.6 
duplications per AFR sample, with trend similar to EUR samples. However, as we noticed, there 
are clearly higher number and bigger size of homozygous deletions and duplications detected in 
AFR than EUR (Fig. 3.4b, d). This might be due to the fact that the WES data was mapped to a 
human genome reference with majority of reference samples from European ancestry. The high 
number of homozygous deletion and duplication in the AFR might just be gaps and diversities 
that was not captured in the reference genome. However, further investigation of the CNV burden 
differences between AFR samples and EUR samples are necessary. 
3.3.2 Comparison with CLAMMS 
The PMBB samples have been applied to a computational method called Copy number 
estimation using Lattice-Aligned Mixture Models (CLAMMS), which utilize only the WES read 
depth information for CNV detection [149]. On average, iCNV identified more and bigger CNV 
cases comparing the CLAMMS, which is contributed by integration of both allele frequency 
information and additional resources of SNP array. Fig. 3.5 shows an example of 1Mb regions of 
TG gene where iCNV detect CNVs but CLAMMS do not. Sample UPENN6848 and sample 
UPENN10001043 both show that the deletion regions are covered by only few exons but many 
SNPs, thus iCNV provides additional sensitivity as it adopts SNP information (Fig. 3.5bc). Another 
example is 800kb region of gene RIMS2 (Fig. 3.6). For sample UPENN4733, even though both 
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CLAMMS and iCNV detected this duplication, iCNV provides higher resolution in terms of the 
segmentation point with SNP array information (Fig. 3.6b). Sample UPENN10010167 is an 
another example of duplication regions that covered by only few exons but many SNPs (Fig. 
3.6c). Actually, as shown in the iCNV paper, we find that an integrated analysis yields more 
deletion and duplications than single platforms. More importantly, when comparing the integrated 
analysis with a simple intersection or union of results from a separate analysis of each individual 
platform, iCNV achieves specificity close to intersection and sensitivity of the union (Fig. 3.7). A 
signal that is moderate in both platforms would be present in the integrated call set but not in the 
union call set. A signal that is only present in one platform but absent in the other would be 
present in the union call set but not detected during integration. Compared to taking a simple 
union, combining the two platforms improves resolution, thus improving CNV detection power, 
and integration by the hidden Markov model allows one platform to “check” the calls of the other, 
thus improving robustness. 
 Conclusion 
We have detected the CNV profile across 10297 samples in the PMBB with both SNP-array and 
WES data using iCNV. Comparing with method that only utilizes WES read depth features, iCNV 
shows higher sensitivity and robustness. In addition, through a Map-Reduce framework with 
permutation, we reduce the total computation time by 100 folds and allow robust normalization 
step. This work provides an rich resources for understanding CNVs and pave the ways to many 
potential studies of PMBB such as CNV risk score [145], PheWAS analysis [150] and CNV 










Figure 3.1 iCNV analysis pipeline including data normalization, CNV calling and genotyping 
using NGS and array data. For NGS data, the first step is to normalize coverage using CODEX 
and calculate a Poisson log-likelihood ratio (PLR), further converted to a normalized LRR by a z-
transformation. The heterozygous single nucleotide positions are then found and BAF computed 
using SAMTools. For array data, we obtain log R ratios and BAF from raw SNP intensity data, 
then normalize the log R ratios. The integrated Hidden Markov Model takes these inputs and 






Figure 3.2 Map-reduce framework for CNV profiling of PMBB data set. Here, we select the 








Figure 3.3 CNV detection by iCNV (120 example individual chr22, CNV>10kb). Heat map 
indicates CNV scores (blue indicates more likely to be duplication and red indicates more likely to 
be deletion) and CNV calling (dark blue dots: duplication; dark red dots: deletion). Here, each row 




Figure 3.4 Summary statistics of iCNV results. a Distribution of number CNVs per sample 
across 8087 EUR samples. b Distribution of size of CNVs across 8087 EUR samples. c 
Distribution of number CNVs per sample across 2219 AFR samples. d Distribution of size of 




Figure 3.5 iCNV vs. CLAMMS of 1Mb region around gene TG. a UCSC Genome Browser 
shows the CNV calling result at this regions of CLAMMS and iCNV. Here, red bar indicates 
tentative deletion and green bar indicating tentative duplication. Yellow arrow indicates regions of 
focus for b and c. b, c iCNV plot. First panel shows the iCNV score heatmap, with white dots 
indicating deletion detected. Second and third panel show normalized data distribution of 






Figure 3.6 iCNV vs. CLAMMS of 800kb region around gene RIMS2. a UCSC Genome Browser 
shows the CNV calling result at this regions of CLAMMS and iCNV. Here, red bar indicates 
tentative deletion and green bar indicating tentative duplication. b, c iCNV plot. First panel shows 
the iCNV score heatmap, with black dots indicating duplication detected. Second and third panel 
show normalized data distribution of sequencing and SNP. Grey dots indicate intensity, black 




Figure 3.7 Results comparison between intersection or union and iCNV. Precision and 
sensitivity analysis by in silico spike-in, comparing joint and intersection or union of two individual 



















1. Gamazon ER, Stranger BE: The impact of human copy number variation on gene 
expression. Briefings in Functional Genomics 2015, 14:352-357. 
2. Hanks S, Coleman K, Reid S, Plaja A, Firth H, Fitzpatrick D, Kidd A, Mehes K, Nash R, 
Robin N, et al: Constitutional aneuploidy and cancer predisposition caused by 
biallelic mutations in BUB1B. Nat Genet 2004, 36:1159-1161. 
3. Vicente-Duenas C, Hauer J, Cobaleda C, Borkhardt A, Sanchez-Garcia I: Epigenetic 
Priming in Cancer Initiation. Trends Cancer 2018, 4:408-417. 
4. Burrell RA, McGranahan N, Bartek J, Swanton C: The causes and consequences of 
genetic heterogeneity in cancer evolution. Nature 2013, 501:338-345. 
5. Jiang Y, Qiu Y, Minn AJ, Zhang NR: Assessing intratumor heterogeneity and tracking 
longitudinal and spatial clonal evolutionary history by next-generation sequencing. 
Proc Natl Acad Sci U S A 2016, 113:E5528-5537. 
6. Deshwar AG, Vembu S, Yung CK, Jang GH, Stein L, Morris Q: PhyloWGS: 
reconstructing subclonal composition and evolution from whole-genome 
sequencing of tumors. Genome Biol 2015, 16:35. 
7. Zare H, Wang J, Hu A, Weber K, Smith J, Nickerson D, Song C, Witten D, Blau CA, 
Noble WS: Inferring clonal composition from multiple sections of a breast cancer. 
PLoS Comput Biol 2014, 10:e1003703. 
8. Carter SL, Cibulskis K, Helman E, McKenna A, Shen H, Zack T, Laird PW, Onofrio RC, 
Winckler W, Weir BA, et al: Absolute quantification of somatic DNA alterations in 
human cancer. Nat Biotechnol 2012, 30:413-421. 
9. Li B, Li JZ: A general framework for analyzing tumor subclonality using SNP array 
and DNA sequencing data. Genome Biol 2014, 15:473. 
10. Oesper L, Mahmoody A, Raphael BJ: THetA: inferring intra-tumor heterogeneity from 
high-throughput DNA sequencing data. Genome Biol 2013, 14:R80. 
11. Ha G, Roth A, Khattra J, Ho J, Yap D, Prentice LM, Melnyk N, McPherson A, Bashashati 
A, Laks E, et al: TITAN: inference of copy number architectures in clonal cell 
populations from tumor whole-genome sequence data. Genome Res 2014, 24:1881-
1893. 
12. Miller CA, White BS, Dees ND, Griffith M, Welch JS, Griffith OL, Vij R, Tomasson MH, 
Graubert TA, Walter MJ, et al: SciClone: inferring clonal architecture and tracking 
the spatial and temporal patterns of tumor evolution. PLoS Comput Biol 2014, 
10:e1003665. 
13. Navin NE: The first five years of single-cell cancer genomics and beyond. Genome 
Res 2015, 25:1499-1507. 
14. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, Cook K, Stepansky A, 
Levy D, Esposito D, et al: Tumour evolution inferred by single-cell sequencing. 
Nature 2011, 472:90-94. 
15. Wang Y, Waters J, Leung ML, Unruh A, Roh W, Shi X, Chen K, Scheet P, Vattathil S, 
Liang H, et al: Clonal evolution in breast cancer revealed by single nucleus genome 
sequencing. Nature 2014, 512:155-160. 
16. Gao R, Davis A, McDonald TO, Sei E, Shi X, Wang Y, Tsai PC, Casasent A, Waters J, 
Zhang H, et al: Punctuated copy number evolution and clonal stasis in triple-
negative breast cancer. Nat Genet 2016, 48:1119-1130. 
17. Picelli S, Bjorklund AK, Faridani OR, Sagasser S, Winberg G, Sandberg R: Smart-seq2 




18. Klein AM, Mazutis L, Akartuna I, Tallapragada N, Veres A, Li V, Peshkin L, Weitz DA, 
Kirschner MW: Droplet barcoding for single-cell transcriptomics applied to 
embryonic stem cells. Cell 2015, 161:1187-1201. 
19. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, Cahill DP, 
Nahed BV, Curry WT, Martuza RL, et al: Single-cell RNA-seq highlights intratumoral 
heterogeneity in primary glioblastoma. Science 2014, 344:1396-1401. 
20. Chung W, Eum HH, Lee HO, Lee KM, Lee HB, Kim KT, Ryu HS, Kim S, Lee JE, Park 
YH, et al: Single-cell RNA-seq enables comprehensive tumour and immune cell 
profiling in primary breast cancer. Nat Commun 2017, 8:15081. 
21. Kim KT, Lee HW, Lee HO, Song HJ, Jeong da E, Shin S, Kim H, Shin Y, Nam DH, Jeong 
BC, et al: Application of single-cell RNA sequencing in optimizing a combinatorial 
therapeutic strategy in metastatic renal cell carcinoma. Genome Biol 2016, 17:80. 
22. Tirosh I, Izar B, Prakadan SM, Wadsworth MH, 2nd, Treacy D, Trombetta JJ, Rotem A, 
Rodman C, Lian C, Murphy G, et al: Dissecting the multicellular ecosystem of 
metastatic melanoma by single-cell RNA-seq. Science 2016, 352:189-196. 
23. Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, Leeson R, Kanodia A, 
Mei S, Lin JR, et al: A Cancer Cell Program Promotes T Cell Exclusion and 
Resistance to Checkpoint Blockade. Cell 2018, 175:984-997 e924. 
24. Tirosh I, Venteicher AS, Hebert C, Escalante LE, Patel AP, Yizhak K, Fisher JM, Rodman 
C, Mount C, Filbin MG, et al: Single-cell RNA-seq supports a developmental 
hierarchy in human oligodendroglioma. Nature 2016, 539:309-313. 
25. Venteicher AS, Tirosh I, Hebert C, Yizhak K, Neftel C, Filbin MG, Hovestadt V, Escalante 
LE, Shaw ML, Rodman C, et al: Decoupling genetics, lineages, and 
microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science 2017, 
355. 
26. Li H, Courtois ET, Sengupta D, Tan Y, Chen KH, Goh JJL, Kong SL, Chua C, Hon LK, 
Tan WS, et al: Reference component analysis of single-cell transcriptomes 
elucidates cellular heterogeneity in human colorectal tumors. Nat Genet 2017, 
49:708-718. 
27. Macaulay IC, Ponting CP, Voet T: Single-Cell Multiomics: Multiple Measurements 
from Single Cells. Trends Genet 2017, 33:155-168. 
28. Dey SS, Kester L, Spanjaard B, Bienko M, van Oudenaarden A: Integrated genome and 
transcriptome sequencing of the same cell. Nat Biotechnol 2015, 33:285-289. 
29. Macaulay IC, Haerty W, Kumar P, Li YI, Hu TX, Teng MJ, Goolam M, Saurat N, 
Coupland P, Shirley LM, et al: G&T-seq: parallel sequencing of single-cell genomes 
and transcriptomes. Nat Methods 2015, 12:519-522. 
30. Suva ML, Tirosh I: Single-Cell RNA Sequencing in Cancer: Lessons Learned and 
Emerging Challenges. Mol Cell 2019, 75:7-12. 
31. van Galen P, Hovestadt V, Wadsworth Ii MH, Hughes TK, Griffin GK, Battaglia S, Verga 
JA, Stephansky J, Pastika TJ, Lombardi Story J, et al: Single-Cell RNA-Seq Reveals 
AML Hierarchies Relevant to Disease Progression and Immunity. Cell 2019, 
176:1265-1281 e1224. 
32. Nam AS, Kim KT, Chaligne R, Izzo F, Ang C, Taylor J, Myers RM, Abu-Zeinah G, Brand 
R, Omans ND, et al: Somatic mutations and cell identity linked by Genotyping of 
Transcriptomes. Nature 2019, 571:355-360. 
33. Raj A, Peskin CS, Tranchina D, Vargas DY, Tyagi S: Stochastic mRNA synthesis in 
mammalian cells. PLoS Biol 2006, 4:e309. 
34. Jiang Y, Zhang NR, Li M: SCALE: modeling allele-specific gene expression by 
single-cell RNA sequencing. Genome Biol 2017, 18:74. 
35. Padovan-Merhar O, Nair GP, Biaesch AG, Mayer A, Scarfone S, Foley SW, Wu AR, 
Churchman LS, Singh A, Raj A: Single mammalian cells compensate for differences 
115 
 
in cellular volume and DNA copy number through independent global 
transcriptional mechanisms. Mol Cell 2015, 58:339-352. 
36. Zafar H, Wang Y, Nakhleh L, Navin N, Chen K: Monovar: single-nucleotide variant 
detection in single cells. Nat Methods 2016, 13:505-507. 
37. Piskol R, Ramaswami G, Li JB: Reliable identification of genomic variants from RNA-
seq data. Am J Hum Genet 2013, 93:641-651. 
38. Brennecke P, Anders S, Kim JK, Kolodziejczyk AA, Zhang X, Proserpio V, Baying B, 
Benes V, Teichmann SA, Marioni JC, Heisler MG: Accounting for technical noise in 
single-cell RNA-seq experiments. Nat Methods 2013, 10:1093-1095. 
39. Pierson E, Yau C: ZIFA: Dimensionality reduction for zero-inflated single-cell gene 
expression analysis. Genome Biol 2015, 16:241. 
40. Vallejos CA, Marioni JC, Richardson S: BASiCS: Bayesian Analysis of Single-Cell 
Sequencing Data. PLoS Comput Biol 2015, 11:e1004333. 
41. Ding B, Zheng L, Zhu Y, Li N, Jia H, Ai R, Wildberg A, Wang W: Normalization and 
noise reduction for single cell RNA-seq experiments. Bioinformatics 2015, 31:2225-
2227. 
42. Qiu X, Hill A, Packer J, Lin D, Ma YA, Trapnell C: Single-cell mRNA quantification and 
differential analysis with Census. Nat Methods 2017, 14:309-315. 
43. Deng Q, Ramskold D, Reinius B, Sandberg R: Single-cell RNA-seq reveals dynamic, 
random monoallelic gene expression in mammalian cells. Science 2014, 343:193-
196. 
44. Eirew P, Steif A, Khattra J, Ha G, Yap D, Farahani H, Gelmon K, Chia S, Mar C, Wan A, 
et al: Dynamics of genomic clones in breast cancer patient xenografts at single-cell 
resolution. Nature 2015, 518:422-426. 
45. Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, Gronroos E, 
Martinez P, Matthews N, Stewart A, et al: Intratumor heterogeneity and branched 
evolution revealed by multiregion sequencing. N Engl J Med 2012, 366:883-892. 
46. Shi YJ, Tsang JY, Ni YB, Tse GM: Intratumoral Heterogeneity in Breast Cancer: A 
Comparison of Primary and Metastatic Breast Cancers. Oncologist 2017, 22:487-
490. 
47. Ribas A, Wolchok JD: Cancer immunotherapy using checkpoint blockade. Science 
2018, 359:1350-1355. 
48. Schumacher TN, Schreiber RD: Neoantigens in cancer immunotherapy. Science 
2015, 348:69-74. 
49. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, 
Wong P, Ho TS, et al: Cancer immunology. Mutational landscape determines 
sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015, 348:124-
128. 
50. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, 
Spasic M, Henry G, Ciobanu V, et al: PD-1 blockade induces responses by inhibiting 
adaptive immune resistance. Nature 2014, 515:568-571. 
51. Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, 
Xu B, Dada H, Odorizzi PM, et al: Radiation and dual checkpoint blockade activate 
non-redundant immune mechanisms in cancer. Nature 2015, 520:373-377. 
52. Benci JL, Johnson LR, Choa R, Xu Y, Qiu J, Zhou Z, Xu B, Ye D, Nathanson KL, June 
CH, et al: Opposing Functions of Interferon Coordinate Adaptive and Innate 
Immune Responses to Cancer Immune Checkpoint Blockade. Cell 2019, 178:933-
948 e914. 
53. Patel SA, Minn AJ: Combination Cancer Therapy with Immune Checkpoint 
Blockade: Mechanisms and Strategies. Immunity 2018, 48:417-433. 
54. Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, 
Daniels GA, Kurzrock R: Tumor Mutational Burden as an Independent Predictor of 
116 
 
Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther 2017, 16:2598-
2608. 
55. Rosenthal R, Cadieux EL, Salgado R, Bakir MA, Moore DA, Hiley CT, Lund T, Tanic M, 
Reading JL, Joshi K, et al: Neoantigen-directed immune escape in lung cancer 
evolution. Nature 2019, 567:479-485. 
56. Navin NE: Cancer genomics: one cell at a time. Genome Biol 2014, 15:452. 
57. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich 
A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: Gene set enrichment analysis: a 
knowledge-based approach for interpreting genome-wide expression profiles. Proc 
Natl Acad Sci U S A 2005, 102:15545-15550. 
58. Naxerova K, Reiter JG, Brachtel E, Lennerz JK, van de Wetering M, Rowan A, Cai T, 
Clevers H, Swanton C, Nowak MA, et al: Origins of lymphatic and distant metastases 
in human colorectal cancer. Science 2017, 357:55-60. 
59. Wong JS, Warren LE, Bellon JR: Management of the Regional Lymph Nodes in Early-
Stage Breast Cancer. Semin Radiat Oncol 2016, 26:37-44. 
60. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He 
X, Hu Z, et al: Supervised risk predictor of breast cancer based on intrinsic 
subtypes. J Clin Oncol 2009, 27:1160-1167. 
61. Zhang JY, Zhang F, Hong CQ, Giuliano AE, Cui XJ, Zhou GJ, Zhang GJ, Cui YK: Critical 
protein GAPDH and its regulatory mechanisms in cancer cells. Cancer Biol Med 
2015, 12:10-22. 
62. Tarrado-Castellarnau M, Diaz-Moralli S, Polat IH, Sanz-Pamplona R, Alenda C, Moreno 
V, Castells A, Cascante M: Glyceraldehyde-3-phosphate dehydrogenase is 
overexpressed in colorectal cancer onset. Translational Medicine Communications 
2017, 2:6. 
63. Mann M, Cortez V, Vadlamudi RK: Epigenetics of estrogen receptor signaling: role in 
hormonal cancer progression and therapy. Cancers (Basel) 2011, 3:1691-1707. 
64. Green KA, Carroll JS: Oestrogen-receptor-mediated transcription and the influence 
of co-factors and chromatin state. Nat Rev Cancer 2007, 7:713-722. 
65. Dreijerink KM, Mulder KW, Winkler GS, Hoppener JW, Lips CJ, Timmers HT: Menin 
links estrogen receptor activation to histone H3K4 trimethylation. Cancer Res 2006, 
66:4929-4935. 
66. Kim H, Heo K, Kim JH, Kim K, Choi J, An W: Requirement of histone 
methyltransferase SMYD3 for estrogen receptor-mediated transcription. J Biol 
Chem 2009, 284:19867-19877. 
67. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr., Kinzler KW: Cancer 
genome landscapes. Science 2013, 339:1546-1558. 
68. Tokheim CJ, Papadopoulos N, Kinzler KW, Vogelstein B, Karchin R: Evaluating the 
evaluation of cancer driver genes. Proc Natl Acad Sci U S A 2016, 113:14330-14335. 
69. Zhang W, Bojorquez-Gomez A, Velez DO, Xu G, Sanchez KS, Shen JP, Chen K, Licon 
K, Melton C, Olson KM, et al: A global transcriptional network connecting noncoding 
mutations to changes in tumor gene expression. Nat Genet 2018, 50:613-620. 
70. Cuykendall TN, Rubin MA, Khurana E: Non-coding genetic variation in cancer. Curr 
Opin Syst Biol 2017, 1:9-15. 
71. Singh M, Al-Eryani G, Carswell S, Ferguson JM, Blackburn J, Barton K, Roden D, Luciani 
F, Giang Phan T, Junankar S, et al: High-throughput targeted long-read single cell 
sequencing reveals the clonal and transcriptional landscape of lymphocytes. Nat 
Commun 2019, 10:3120. 
72. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, 




73. Li B, Dewey CN: RSEM: accurate transcript quantification from RNA-Seq data with 
or without a reference genome. BMC Bioinformatics 2011, 12:323. 
74. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, 
Altshuler D, Gabriel S, Daly M, DePristo MA: The Genome Analysis Toolkit: a 
MapReduce framework for analyzing next-generation DNA sequencing data. 
Genome Res 2010, 20:1297-1303. 
75. Skelly DA, Johansson M, Madeoy J, Wakefield J, Akey JM: A powerful and flexible 
statistical framework for testing hypotheses of allele-specific gene expression 
from RNA-seq data. Genome Res 2011, 21:1728-1737. 
76. Ward JH: Hierarchical Grouping to Optimize an Objective Function. Journal of the 
American Statistical Association 1963, 58:236-&. 
77. Goutte C, Hansen LK, Liptrot MG, Rostrup E: Feature-space clustering for fMRI meta-
analysis. Hum Brain Mapp 2001, 13:165-183. 
78. Urrutia E, Chen H, Zhou Z, Zhang NR, Jiang Y: Integrative pipeline for profiling DNA 
copy number and inferring tumor phylogeny. Bioinformatics 2018, 34:2126-2128. 
79. Pfeiffer F, Grober C, Blank M, Handler K, Beyer M, Schultze JL, Mayer G: Systematic 
evaluation of error rates and causes in short samples in next-generation 
sequencing. Sci Rep 2018, 8:10950. 
80. Li B, Chen W, Zhan X, Busonero F, Sanna S, Sidore C, Cucca F, Kang HM, Abecasis 
GR: A likelihood-based framework for variant calling and de novo mutation 
detection in families. PLoS Genet 2012, 8:e1002944. 
81. Schliep KP: phangorn: phylogenetic analysis in R. Bioinformatics 2011, 27:592-593. 
82. Finak G, McDavid A, Yajima M, Deng J, Gersuk V, Shalek AK, Slichter CK, Miller HW, 
McElrath MJ, Prlic M, et al: MAST: a flexible statistical framework for assessing 
transcriptional changes and characterizing heterogeneity in single-cell RNA 
sequencing data. Genome Biol 2015, 16:278. 
83. Korthauer KD, Chu LF, Newton MA, Li Y, Thomson J, Stewart R, Kendziorski C: A 
statistical approach for identifying differential distributions in single-cell RNA-seq 
experiments. Genome Biol 2016, 17:222. 
84. Butler A, Hoffman P, Smibert P, Papalexi E, Satija R: Integrating single-cell 
transcriptomic data across different conditions, technologies, and species. Nat 
Biotechnol 2018, 36:411-420. 
85. Wang K, Li M, Hakonarson H: ANNOVAR: functional annotation of genetic variants 
from high-throughput sequencing data. Nucleic Acids Res 2010, 38:e164. 
86. Karosiene E, Lundegaard C, Lund O, Nielsen M: NetMHCcons: a consensus method 
for the major histocompatibility complex class I predictions. Immunogenetics 2012, 
64:177-186. 
87. Stuart T, Satija R: Integrative single-cell analysis. Nat Rev Genet 2019, 20:257-272. 
88. Peterson VM, Zhang KX, Kumar N, Wong J, Li L, Wilson DC, Moore R, McClanahan TK, 
Sadekova S, Klappenbach JA: Multiplexed quantification of proteins and transcripts 
in single cells. Nat Biotechnol 2017, 35:936-939. 
89. Stoeckius M, Hafemeister C, Stephenson W, Houck-Loomis B, Chattopadhyay PK, 
Swerdlow H, Satija R, Smibert P: Simultaneous epitope and transcriptome 
measurement in single cells. Nat Methods 2017, 14:865-868. 
90. Wang X, Allen WE, Wright MA, Sylwestrak EL, Samusik N, Vesuna S, Evans K, Liu C, 
Ramakrishnan C, Liu J, et al: Three-dimensional intact-tissue sequencing of single-
cell transcriptional states. Science 2018, 361. 
91. Regev A, Teichmann SA, Lander ES, Amit I, Benoist C, Birney E, Bodenmiller B, 
Campbell P, Carninci P, Clatworthy M, et al: The Human Cell Atlas. Elife 2017, 6. 
92. Villani AC, Satija R, Reynolds G, Sarkizova S, Shekhar K, Fletcher J, Griesbeck M, Butler 
A, Zheng S, Lazo S, et al: Single-cell RNA-seq reveals new types of human blood 
dendritic cells, monocytes, and progenitors. Science 2017, 356. 
118 
 
93. Liu Y, Beyer A, Aebersold R: On the Dependency of Cellular Protein Levels on mRNA 
Abundance. Cell 2016, 165:535-550. 
94. Svensson V, Natarajan KN, Ly LH, Miragaia RJ, Labalette C, Macaulay IC, Cvejic A, 
Teichmann SA: Power analysis of single-cell RNA-sequencing experiments. Nat 
Methods 2017, 14:381-387. 
95. Zhao BS, Roundtree IA, He C: Post-transcriptional gene regulation by mRNA 
modifications. Nat Rev Mol Cell Biol 2017, 18:31-42. 
96. Jackson RJ, Hellen CU, Pestova TV: The mechanism of eukaryotic translation 
initiation and principles of its regulation. Nat Rev Mol Cell Biol 2010, 11:113-127. 
97. Mowen KA, David M: Unconventional post-translational modifications in 
immunological signaling. Nat Immunol 2014, 15:512-520. 
98. Schwartz AL: Cell biology of intracellular protein trafficking. Annu Rev Immunol 
1990, 8:195-229. 
99. Roux PP, Topisirovic I: Signaling Pathways Involved in the Regulation of mRNA 
Translation. Mol Cell Biol 2018, 38. 
100. Wang J, Agarwal D, Huang M, Hu G, Zhou Z, Ye C, Zhang NR: Data denoising with 
transfer learning in single-cell transcriptomics. Nat Methods 2019, 16:875-878. 
101. Webb S: Deep learning for biology. Nature 2018, 554:555-557. 
102. Tang B, Pan Z, Yin K, Khateeb A: Recent Advances of Deep Learning in 
Bioinformatics and Computational Biology. Front Genet 2019, 10:214. 
103. Lopez R, Regier J, Cole MB, Jordan MI, Yosef N: Deep generative modeling for 
single-cell transcriptomics. Nat Methods 2018, 15:1053-1058. 
104. Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM, 3rd, Hao Y, 
Stoeckius M, Smibert P, Satija R: Comprehensive Integration of Single-Cell Data. Cell 
2019, 177:1888-1902 e1821. 
105. Martins PS, Brunialti MK, Martos LS, Machado FR, Assuncao MS, Blecher S, Salomao 
R: Expression of cell surface receptors and oxidative metabolism modulation in 
the clinical continuum of sepsis. Crit Care 2008, 12:R25. 
106. Chen L, Flies DB: Molecular mechanisms of T cell co-stimulation and co-inhibition. 
Nat Rev Immunol 2013, 13:227-242. 
107. Fromm P, Papadimitrious M, Hsu J, Larsen SR, Gibson J, Bradstock K, Kupresanin F, 
Clark G, Hart DNJ: CD16+Dendritic Cells Are a Unique Myeloid Antigen Presenting 
Cell Population. Blood 2016, 128. 
108. D'Arena G, Musto P, Cascavilla N, Di Giorgio G, Fusilli S, Zendoli F, Carotenuto M: Flow 
cytometric characterization of human umbilical cord blood lymphocytes: 
immunophenotypic features. Haematologica 1998, 83:197-203. 
109. Clavarino G, Delouche N, Vettier C, Laurin D, Pernollet M, Raskovalova T, Cesbron JY, 
Dumestre-Perard C, Jacob MC: Novel Strategy for Phenotypic Characterization of 
Human B Lymphocytes from Precursors to Effector Cells by Flow Cytometry. Plos 
One 2016, 11. 
110. Van Acker HH, Capsomidis A, Smits EL, Van Tendeloo VF: CD56 in the Immune 
System: More Than a Marker for Cytotoxicity? Front Immunol 2017, 8:892. 
111. Tsukerman P, Stern-Ginossar N, Yamin R, Ophir Y, Stanietsky AM, Mandelboim O: 
Expansion of CD16 positive and negative human NK cells in response to tumor 
stimulation. Eur J Immunol 2014, 44:1517-1525. 
112. Poli A, Michel T, Theresine M, Andres E, Hentges F, Zimmer J: CD56(bright) natural 
killer (NK) cells: an important NK cell subset. Immunology 2009, 126:458-465. 
113. Wendt K, Wilk E, Buyny S, Buer J, Schmidt RE, Jacobs R: Gene and protein 
characteristics reflect functional diversity of CD56(dim) and CD56(bright) NK cells. 
Journal of Leukocyte Biology 2006, 80:1529-1541. 
119 
 
114. d'Angeac AD, Monier S, Pilling D, Travaglio-Encinoza A, Reme T, Salmon M: CD57+ T 
lymphocytes are derived from CD57- precursors by differentiation occurring in late 
immune responses. Eur J Immunol 1994, 24:1503-1511. 
115. Musha N, Yoshida Y, Sugahara S, Yamagiwa S, Koya T, Watanabe H, Hatakeyama K, 
Abo T: Expansion of CD56+ NK T and gamma delta T cells from cord blood of 
human neonates. Clin Exp Immunol 1998, 113:220-228. 
116. Dalle JH, Menezes J, Wagner E, Blagdon M, Champagne J, Champagne MA, Duval M: 
Characterization of cord blood natural killer cells: implications for transplantation 
and neonatal infections. Pediatr Res 2005, 57:649-655. 
117. Pollyea DA, Jordan CT: Therapeutic targeting of acute myeloid leukemia stem cells. 
Blood 2017, 129:1627-1635. 
118. McKenzie MD, Ghisi M, Oxley EP, Ngo S, Cimmino L, Esnault C, Liu RJ, Salmon JM, 
Bell CC, Ahmed N, et al: Interconversion between Tumorigenic and Differentiated 
States in Acute Myeloid Leukemia. Cell Stem Cell 2019, 25:258-+. 
119. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K: Development of 
Monocytes, Macrophages, and Dendritic Cells. Science 2010, 327:656-661. 
120. Jang JH, Yoo EH, Kim HJ, Kim DH, Jung CW, Kim SH: Acute myeloid leukemia with 
del(X)(p21) and cryptic RUNX1/RUNX1T1 from ins(8;21)(q22;q22q22) revealed by 
atypical FISH signals. Ann Clin Lab Sci 2010, 40:80-84. 
121. Moroi K, Sato T: Comparison between procaine and isocarboxazid metabolism in 
vitro by a liver microsomal amidase-esterase. Biochem Pharmacol 1975, 24:1517-
1521. 
122. Shang L, Chen X, Liu Y, Cai X, Shi Y, Shi L, Li Y, Song Z, Zheng B, Sun W, et al: The 
immunophenotypic characteristics and flow cytometric scoring system of acute 
myeloid leukemia with t(8;21) (q22;q22); RUNX1-RUNX1T1. Int J Lab Hematol 2019, 
41:23-31. 
123. Naik J, Themeli M, de Jong-Korlaar R, Ruiter RWJ, Poddighe PJ, Yuan HP, Bruijn JDD, 
Ossenkoppele GJ, Zweegman S, Smit L, et al: CD38 as a therapeutic target for adult 
acute myeloid leukemia and T-cell acute lymphoblastic leukemia. Haematologica 
2019, 104:E100-E103. 
124. Eveillard M, Floc'h V, Robillard N, Debord C, Wuilleme S, Garand R, Rialland F, Thomas 
C, Peterlin P, Guillaume T, et al: CD38 Expression in B-Lineage Acute Lymphoblastic 
Leukemia, a Possible Target for Immunotherapy. Blood 2016, 128. 
125. An GZ: The effects of adding noise during backpropagation training on a 
generalization performance. Neural Computation 1996, 8:643-674. 
126. Reed R, MarksII RJ: Neural smithing: supervised learning in feedforward artificial neural 
networks. Mit Press; 1999. 
127. Andrews TS, Hemberg M: False signals induced by single-cell imputation. F1000Res 
2018, 7:1740. 
128. LeCun Y, Bengio Y, Hinton G: Deep learning. Nature 2015, 521:436-444. 
129. Kingma D, Ba J: Adam: a method for stochastic optimization (2014). arXiv preprint 
arXiv:14126980 2015, 15. 
130. Freeman JL, Perry GH, Feuk L, Redon R, McCarroll SA, Altshuler DM, Aburatani H, 
Jones KW, Tyler-Smith C, Hurles ME, et al: Copy number variation: new insights in 
genome diversity. Genome Res 2006, 16:949-961. 
131. McCarroll SA, Altshuler DM: Copy-number variation and association studies of 
human disease. Nat Genet 2007, 39:S37-42. 
132. Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, Fiegler H, Shapero MH, 
Carson AR, Chen W, et al: Global variation in copy number in the human genome. 
Nature 2006, 444:444-454. 
120 
 
133. Diskin SJ, Hou C, Glessner JT, Attiyeh EF, Laudenslager M, Bosse K, Cole K, Mosse 
YP, Wood A, Lynch JE, et al: Copy number variation at 1q21.1 associated with 
neuroblastoma. Nature 2009, 459:987-991. 
134. Glessner JT, Wang K, Cai G, Korvatska O, Kim CE, Wood S, Zhang H, Estes A, Brune 
CW, Bradfield JP, et al: Autism genome-wide copy number variation reveals 
ubiquitin and neuronal genes. Nature 2009, 459:569-573. 
135. McCarroll SA, Huett A, Kuballa P, Chilewski SD, Landry A, Goyette P, Zody MC, Hall JL, 
Brant SR, Cho JH, et al: Deletion polymorphism upstream of IRGM associated with 
altered IRGM expression and Crohn's disease. Nat Genet 2008, 40:1107-1112. 
136. Fromer M, Moran JL, Chambert K, Banks E, Bergen SE, Ruderfer DM, Handsaker RE, 
McCarroll SA, O'Donovan MC, Owen MJ, et al: Discovery and statistical genotyping 
of copy-number variation from whole-exome sequencing depth. Am J Hum Genet 
2012, 91:597-607. 
137. Jiang Y, Oldridge DA, Diskin SJ, Zhang NR: CODEX: a normalization and copy 
number variation detection method for whole exome sequencing. Nucleic Acids Res 
2015, 43:e39. 
138. Wang K, Li M, Hadley D, Liu R, Glessner J, Grant SF, Hakonarson H, Bucan M: 
PennCNV: an integrated hidden Markov model designed for high-resolution copy 
number variation detection in whole-genome SNP genotyping data. Genome Res 
2007, 17:1665-1674. 
139. Abyzov A, Urban AE, Snyder M, Gerstein M: CNVnator: an approach to discover, 
genotype, and characterize typical and atypical CNVs from family and population 
genome sequencing. Genome Res 2011, 21:974-984. 
140. Pinkel D, Segraves R, Sudar D, Clark S, Poole I, Kowbel D, Collins C, Kuo WL, Chen C, 
Zhai Y, et al: High resolution analysis of DNA copy number variation using 
comparative genomic hybridization to microarrays. Nat Genet 1998, 20:207-211. 
141. Carter NP: Methods and strategies for analyzing copy number variation using DNA 
microarrays. Nat Genet 2007, 39:S16-21. 
142. Chiang DY, Getz G, Jaffe DB, O'Kelly MJ, Zhao X, Carter SL, Russ C, Nusbaum C, 
Meyerson M, Lander ES: High-resolution mapping of copy-number alterations with 
massively parallel sequencing. Nat Methods 2009, 6:99-103. 
143. Zhao M, Wang Q, Wang Q, Jia P, Zhao Z: Computational tools for copy number 
variation (CNV) detection using next-generation sequencing data: features and 
perspectives. BMC Bioinformatics 2013, 14 Suppl 11:S1. 
144. Zhou Z, Wang W, Wang LS, Zhang NR: Integrative DNA copy number detection and 
genotyping from sequencing and array-based platforms. Bioinformatics 2018, 
34:2349-2355. 
145. Aguirre M, Rivas MA, Priest J: Phenome-wide Burden of Copy-Number Variation in 
the UK Biobank. Am J Hum Genet 2019, 105:373-383. 
146. Takahashi PY, Jenkins GD, Welkie BP, McDonnell SK, Evans JM, Cerhan JR, Olson JE, 
Thibodeau SN, Cicek MS, Ryu E: Association of mitochondrial DNA copy number 
with self-rated health status. Appl Clin Genet 2018, 11:121-127. 
147. Dean J, Ghemawat S: Mapreduce: Simplified data processing on large clusters. 
Communications of the Acm 2008, 51:107-113. 
148. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, 
Durbin R, Genome Project Data Processing S: The Sequence Alignment/Map format 
and SAMtools. Bioinformatics 2009, 25:2078-2079. 
149. Packer JS, Maxwell EK, O'Dushlaine C, Lopez AE, Dewey FE, Chernomorsky R, Baras 
A, Overton JD, Habegger L, Reid JG: CLAMMS: a scalable algorithm for calling 
common and rare copy number variants from exome sequencing data. 
Bioinformatics 2016, 32:133-135. 
121 
 
150. Denny JC, Ritchie MD, Basford MA, Pulley JM, Bastarache L, Brown-Gentry K, Wang D, 
Masys DR, Roden DM, Crawford DC: PheWAS: demonstrating the feasibility of a 
phenome-wide scan to discover gene-disease associations. Bioinformatics 2010, 
26:1205-1210. 
 
